niacin has been researched along with Hyperlipemia in 299 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy and safety of ezetimibe/simvastatin (E/S) plus extended-release niacin (N) in hyperlipidaemic patients with diabetes mellitus (DM), metabolic syndrome (MetS) without DM (MetS/non-DM) or neither (non-DM/non-MetS)." | 9.14 | Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. ( Fazio, S; Guyton, JR; Lin, J; Shah, A; Tershakovec, AM; Tomassini, JE, 2010) |
| "To assess the lipid-lowering effects and safety of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia." | 9.08 | A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group. ( Black, DM; Kafonek, S; Koren, M; McCormick, LS; McKenney, JM; Weiss, S, 1998) |
| "To review the pathophysiology and clinical relevance for using niacin to treat the metabolic syndrome." | 8.82 | The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin. ( Ito, MK, 2004) |
| "Two 65-year-old white men with coronary heart disease, given niacin therapy for dyslipidemia for 5 months, developed intense dental and gingival pain that was associated with increases in dose and that was relieved with discontinuance of niacin treatment." | 7.70 | Dental and gingival pain as side effects of niacin therapy. ( Davis, WJ; Gordon, NF; Leighton, RF; Small, GS; Ward, ES, 1998) |
| "Postprandial (non-fasting) hyperlipemia is characterized by increased blood levels of exogenous triglycerides (TG) in the form of apolipoprotein (apo) B48-containing TG-rich lipoproteins (TRL), which have a causal role in the pathogenesis and progression of cardiovascular disease (CVD)." | 6.53 | Pharmacological Effects of Niacin on Acute Hyperlipemia. ( Abia, R; Bermudez, B; la Paz, SM; Lopez, S; Muriana, FJ; Naranjo, MC, 2016) |
| "Niacin is considered to be a powerful drug for the treatment of lipid and lipoprotein abnormalities connected with "residual cardiovascular risk", which persist in high-risk patients even when the target goals of LDL-C are achieved with statin therapy." | 6.52 | Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place? ( Hromádka, R; Perlík, F; Staňková, B; Tvrzická, E; Vecka, M; Žák, A; Zeman, M, 2015) |
| "Bezafibrate was effective hypolipidemic agent in normal rats, but addition of nicotinic acid has certainly improved the effectiveness further which could be of clinical significance." | 5.28 | Effect of bezafibrate & nicotinic acid on triton induced hyperlipidemias in CFY rats. ( Krishnamurthy, A; Thapar, GS, 1991) |
| "To compare the effects of combination niacin extended-release + simvastatin (NER/S) versus atorvastatin alone on apolipoproteins and lipid fractions in a post hoc analysis from SUPREME, a study which compared the lipid effects of niacin extended-release + simvastatin and atorvastatin in patients with hyperlipidemia or mixed dyslipidemia." | 5.14 | Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. ( Insull, W; Jiang, P; Krause, S; Padley, RJ; Parreno, RA; Superko, HR; Thakkar, RB; Toth, PP, 2010) |
| "To assess the efficacy and safety of ezetimibe/simvastatin (E/S) plus extended-release niacin (N) in hyperlipidaemic patients with diabetes mellitus (DM), metabolic syndrome (MetS) without DM (MetS/non-DM) or neither (non-DM/non-MetS)." | 5.14 | Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. ( Fazio, S; Guyton, JR; Lin, J; Shah, A; Tershakovec, AM; Tomassini, JE, 2010) |
| "To evaluate the efficacy and safety of extended-release niacin (niacin ER) either alone or in combination with atorvastatin for the lipid profile modification in the patients with coronary heart disease (CHD) and its equivalents." | 5.12 | [Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification]. ( Duan, J; Li, XP; Tan, MY; Xu, ZM; Zhang, DQ; Zhao, SP, 2006) |
| "To assess the lipid-lowering effects and safety of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia." | 5.08 | A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group. ( Black, DM; Kafonek, S; Koren, M; McCormick, LS; McKenney, JM; Weiss, S, 1998) |
| "It appears from this pilot study that preceding niacin with 325 mg of aspirin will decrease the warmth and flushing associated with niacin." | 5.07 | The effect of aspirin on niacin-induced cutaneous reactions. ( Fowler, SF; Hainer, BL; Price, SO; Whelan, AM, 1992) |
| "To minimize the cutaneous flushing symptoms associated with niacin use, a time-release capsule form of niacin has been formulated." | 5.05 | Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. ( Albers, JJ; Burrows, E; Ginsberg, J; Hoff, C; Knopp, RH; Ogilvie, JT; Poole, M; Retzlaff, B; Warnick, GR, 1985) |
| " In this article, we briefly review the clinical trial data on the efficacy, safety and influence on non-lipid atherosclerosis factors of combined therapy statin with fibrates, statin with nicotinic acid and statin with ezetimibe." | 4.84 | [Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors]. ( Balcerak, M; Broncel, M; Chojnowska-Jezierska, J, 2007) |
| " Dyslipidemia in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis may improve with use of statins, fibrates, niacin, and thiazolidinediones, but the data are presently very limited." | 4.82 | Management of dyslipidemia in patients with complicated metabolic syndrome. ( Davidson, MH, 2005) |
| "To review the pathophysiology and clinical relevance for using niacin to treat the metabolic syndrome." | 4.82 | The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin. ( Ito, MK, 2004) |
| " Recently, it has been shown that some of the most prescribed fibrates cause hyperhomocysteinemia, which itself has been recognised as a cardiovascular risk factor." | 4.82 | The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. ( Dierkes, J; Luley, C; Westphal, S, 2004) |
| " Many of these patients, as well as persons at heightened risk for cardiovascular disease because of a range of heritable conditions (eg, familial hypercholesterolemia, familial combined hyperlipidemia), will undoubtedly require binary or ternary regimens involving statins in concert with niacin, fibric-acid derivatives, or bile acid resins." | 4.81 | Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century. ( Jacobson, TA, 2001) |
| "This study determined time trends between 2007 and 2011 for statin and nonstatin lipid-lowering therapy (niacin, fibrates, bile acid sequestrants, and ezetimibe) use among Medicare beneficiaries with coronary heart disease (CHD) in light of emerging clinical trial evidence." | 3.81 | Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease: A Retrospective Cohort Study in the Medicare Population 2007 to 2011. ( Bittner, V; Deng, L; Farkouh, ME; Glasser, SP; Kent, ST; Muntner, P; Rosenson, RS; Taylor, B, 2015) |
| "In the field of dyslipidemia and metabolic syndrome, four innovative therapies are reviewed: Ezetimibe (Ezétrol) is a selective cholesterol absorption inhibitor." | 3.73 | [Innovative therapies in metabolic diseases: ezetimibe (Ezétrol), nicotinic acid (Niaspan), acids omega-3 (Omacor), rimonabant (Acomplia)]. ( Ducobu, J, 2005) |
| "Two 65-year-old white men with coronary heart disease, given niacin therapy for dyslipidemia for 5 months, developed intense dental and gingival pain that was associated with increases in dose and that was relieved with discontinuance of niacin treatment." | 3.70 | Dental and gingival pain as side effects of niacin therapy. ( Davis, WJ; Gordon, NF; Leighton, RF; Small, GS; Ward, ES, 1998) |
| "High-dose niacin has versatile and substantial efficacy for the treatment of hyperlipidemias, but its utility is compromised by various side effects, the most serious of which is liver damage." | 3.70 | Co-administration of equimolar doses of betaine may alleviate the hepatotoxic risk associated with niacin therapy. ( McCarty, MF, 2000) |
| "Niacin (nicotinic acid) is a widely used agent in the treatment of hyperlipidemias characterized by elevated low-density lipoprotein and very-low-density lipoprotein." | 3.68 | Hepatotoxicity associated with sustained-release niacin. ( Berry, RS; Dalton, TA, 1992) |
| " Adverse experiences (AEs) typically associated with niacin (flushing, pruritus, increased glucose, increased uric acid) were more common with ERN/LRPT+SIMVA, and hepatic-related laboratory AEs were more common with ATORVA." | 2.78 | Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. ( Blomqvist, P; Chen, E; Chen, F; Davidson, M; Maccubbin, D; McKenney, JM; Sirah, W; Sisk, CM; Yan, L, 2013) |
| " The primary end point, the safety of E/S plus niacin, included prespecified adverse events (ie, liver, muscle, discontinuations due to flushing, gallbladder-related, cholecystectomy, fasting glucose changes, new-onset diabetes)." | 2.75 | Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. ( Adewale, AJ; Fazio, S; Guyton, JR; Polis, AB; Ryan, NW; Tershakovec, AM; Tomassini, JE, 2010) |
| "Niacin treatment significantly increased TRL apoB-48 FCR but had no effect on apoB-48 PR." | 2.73 | Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. ( Ai, M; Asztalos, BF; Barrett, PH; Buchsbaum, A; Diffenderfer, MR; Dolnikowski, GG; Horvath, KV; Lamon-Fava, S; Lichtenstein, AH; Matthan, NR; Nyaku, M; Otokozawa, S; Schaefer, EJ, 2008) |
| "Dyslipidemia is one of the main risk factors for atherosclerosis, usually the underlying cause of cardiovascular diseases which are the major cause of morbidity and mortality in developed countries." | 2.72 | Effects of combined dietary supplementation on oxidative and inflammatory status in dyslipidemic subjects. ( Accinni, R; Bamonti, F; Bernacchi, F; Campolo, J; Caruso, R; Ciani, A; Della Noce, C; Ghersi, L; Gorini, M; Grossi, S; Ippolito, S; Lonati, S; Lorenzano, E; Novembrino, C; Rosina, M; Tonini, A, 2006) |
| "This review summarizes the role of hyperlipidemia in ASCVD and treatment strategies for hyperlipidemia in the CKD population." | 2.72 | Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease. ( Bangalore, S; Chaudhry, R; Costa, SP; Lyubarova, R; Mathew, RO; Rosenson, RS; Sidhu, MS, 2021) |
| "Niacin ER/lovastatin was comparable to atorvastatin 10 mg and more effective than simvastatin 20 mg in reducing LDL cholesterol, was more effective in increasing HDL cholesterol than either atorvastatin or simvastatin, and provided greater global improvements in non-HDL cholesterol, triglycerides, and lipoprotein(a)." | 2.71 | Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). ( Bays, HE; Crouse, JR; Dujovne, CA; Hutcheson, AG; Kashyap, ML; McGovern, ME; White, TE, 2003) |
| "Niacin ER/lovastatin was more effective than each of its components for improving levels of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG), and exhibited a clear dose-response effect and additivity across the dosage range." | 2.71 | A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. ( Brazg, R; Hunninghake, DB; Koren, M; McGovern, ME; Murdock, D; Pearson, T; Weiss, S, 2003) |
| "Patients with combined hyperlipidemia and low high-density lipoprotein (HDL) cholesterol levels may benefit from combination therapy with a statin and niacin; therefore, we assessed the efficacy and safety of rosuvastatin and extended-release (ER) niacin alone and in combination in 270 patients with this atherogenic dyslipidemia." | 2.71 | Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. ( Capuzzi, DM; Chitra, RR; Cressman, MD; Hutchinson, HG; Morgan, JM; Weiss, RJ, 2003) |
| "This study compared efficacy of hyperlipidemia (HLE) correction by long-term hypolipidemic diet (HD) and pharmacotherapy (PT) in patients with ischemic heart disease (IHD)." | 2.71 | [Comparative efficiency of prolonged diet and drug therapies for hyperlipidemias in patients with ischemic heart disease]. ( Mal', GS, 2004) |
| " Patients in the southeast and those enrolled by endocrinologists had the lowest compliance and highest adverse event rates." | 2.71 | Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. ( Rubenfire, M, 2004) |
| "ER-niacin's role in the treatment of antiretroviral therapy-associated dyslipidemia requires further evaluation, but the results of this pilot study indicate that it is safe and tolerated and provides a valuable treatment option." | 2.71 | Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. ( Claxton, S; DeMarco, D; Drechsler, H; Gerber, MT; Mondy, KE; Powderly, WG; Stoneman, J; Tebas, P; Yarasheski, KE, 2004) |
| " The most common adverse event was flushing, which caused 10% of patients to withdraw." | 2.70 | Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. ( Bays, HE; Berra, K; Favrot, LK; Guyton, JR; Harper, WL; Kashyap, ML; Kerzner, B; Kwiterovich, PO; McGovern, ME; Nash, SD; Simmons, PD; Toth, PD, 2002) |
| "In patients with atherogenic dyslipidemia, both drugs had important effects on lipoprotein subfractions, which contributed to a reduction in coronary heart disease risk." | 2.70 | Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. ( Black, DM; McCormick, LS; McKenney, JM; Schaefer, EJ; Watkins, ML, 2001) |
| "Etofibrate is a hybrid drug which combines niacin with clofibrate." | 2.70 | Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects. ( Coelho, OR; Mansur, AP; Maranhão, RC; Ramires, JA; Rodrigues-Sobrinho, CR; Sposito, AC, 2001) |
| "Forty-nine middle-aged men with dyslipidemia and established CAD who were undergoing intensive lipid-lowering therapy were studied." | 2.70 | Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. ( Brown, BG; Brunzell, JD; Deeb, SS; Hokanson, JE; Zambon, A, 2001) |
| " Rates of adverse event rates other than flushing were similar for the niacin and placebo groups." | 2.70 | Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. ( Buse, JB; Fitz-Patrick, D; Ganda, OP; Grundy, SM; Kendall, DM; McGovern, ME; Robertson, DD; Rosenson, RS; Sheehan, JP; Tulloch, BR; Vega, GL, 2002) |
| " The most common adverse events were flushing and gastrointestinal disturbance." | 2.69 | Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. ( Alagona, P; Capuzzi, DM; Goldberg, A; Guyton, J; Morgan, JM; Rodgers, J; Sachson, R; Samuel, P, 2000) |
| "Pravastatin treatment of combined hyperlipidemia lowers low-density lipoprotein effectively; nicotinic acid lowers remnant cholesterol and raises high-density lipoprotein." | 2.68 | Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia. ( Grundy, SM; Mostaza, JM; Schulz, I; Vega, GL, 1997) |
| "Acipimox was better tolerated than nicotinic acid but the percentage changes in lipoprotein concentrations were smaller." | 2.67 | The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. ( Knight, BL; O'Connor, B; O'Donnell, M; Perombelon, N; Reaveley, D; Seed, M, 1993) |
| "Postprandial (non-fasting) hyperlipemia is characterized by increased blood levels of exogenous triglycerides (TG) in the form of apolipoprotein (apo) B48-containing TG-rich lipoproteins (TRL), which have a causal role in the pathogenesis and progression of cardiovascular disease (CVD)." | 2.53 | Pharmacological Effects of Niacin on Acute Hyperlipemia. ( Abia, R; Bermudez, B; la Paz, SM; Lopez, S; Muriana, FJ; Naranjo, MC, 2016) |
| "Niacin was the first hypolipidemic drug to significantly reduce both major cardiovascular events and mortality in patients with cardiovascular disease." | 2.53 | Pleiotropic effects of niacin: Current possibilities for its clinical use. ( Hrib, J; Hromádka, R; Perlík, F; Širc, J; Staňková, B; Tvrzická, E; Vecka, M; Žák, A; Zeman, M, 2016) |
| "Niacin is considered to be a powerful drug for the treatment of lipid and lipoprotein abnormalities connected with "residual cardiovascular risk", which persist in high-risk patients even when the target goals of LDL-C are achieved with statin therapy." | 2.52 | Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place? ( Hromádka, R; Perlík, F; Staňková, B; Tvrzická, E; Vecka, M; Žák, A; Zeman, M, 2015) |
| "Hyperlipidemia is common in dogs, and can be either primary or secondary to other diseases." | 2.46 | Lipid metabolism and hyperlipidemia in dogs. ( Steiner, JM; Xenoulis, PG, 2010) |
| "Fifth, combined hyperlipidemia is the most common lipid disorder, has the strongest risk for CVD, and combines elevated LDL, hypertriglyceridemia, and low HDL." | 2.44 | Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. ( Atkinson, B; Dowdy, A; Knopp, RH; Paramsothy, P, 2008) |
| "Niacin has been used for decades in the treatment of patients with disturbed lipid and lipoprotein metabolism, this being the main cause of atherosclerotic changes in cardiovascular diseases." | 2.44 | [Niacin in therapy]. ( Bryła, J; Nagalski, A, 2007) |
| "Niacin has a substantial HDL-C raising effect, and also may beneficially alter total cholesterol, LDL-C and triglyceride levels." | 2.44 | Present-day uses of niacin: effects on lipid and non-lipid parameters. ( Karas, RH; Kuvin, JT; Sanyal, S, 2007) |
| "The approach to the management of hyperlipidemia has evolved dramatically over the past decade." | 2.43 | Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events. ( Balbisi, EA, 2006) |
| "Both diabetes and metabolic syndrome are associated with a clustering of cardiovascular risk factors." | 2.43 | Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. ( Betteridge, J; Shepherd, J; Van Gaal, L, 2005) |
| " The pharmacological dosage (approximately 0,5-4,5 g/day) substantially influences the plasma lipid and lipoprotein concentrations: decreases VLDL and LDL concentrations, changes the profile of LDL subfractions towards the larger particles as well as particles with lower density; it also profoundly increases the concentration of HDL-C in consequence of elevated concentration of HDL2 subfraction." | 2.43 | [Nicotinic acid: an unjustly neglected remedy]. ( Tvrzická, E; Vecka, M; Zák, A; Zeman, M, 2006) |
| "Dyslipidemia is characterized by increased triglyceride-rich lipoproteins; low high-density lipoprotein cholesterol; small, dense low-density lipoprotein particles; increased postprandial lipemia; and abnormal apolipoprotein A1 and B metabolism." | 2.42 | Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. ( Cottrell, DA; Falko, JM; Marshall, BJ, 2003) |
| " Extended-release niacin, also given once daily, has an absorption rate intermediate between the other formulations and is associated with fewer flushing and gastrointestinal symptoms without increasing hepatotoxic risk." | 2.42 | New perspectives on the use of niacin in the treatment of lipid disorders. ( McKenney, J, 2004) |
| "Niacin promotes angiographic regression when used in combination with other drugs that lower LDL cholesterol and can reduce cardiovascular risk in patients with coronary heart disease." | 2.42 | Clinical update on the use of niacin for the treatment of dyslipidemia. ( Berra, K, 2004) |
| "Niacin has been known to be an effective treatment of dyslipidemia for almost half a century." | 2.42 | Niacin as a component of combination therapy for dyslipidemia. ( Miller, M, 2003) |
| "Niacin has long been known to improve concentrations of all major lipids and lipoproteins, but it also has consistently favorable effects on subclass distribution." | 2.42 | The effects of niacin on lipoprotein subclass distribution. ( Capuzzi, DM; Carey, CM; Lincoff, A; Morgan, JM, 2004) |
| "Niacin ER has been studied extensively in combination therapy with statins, including lovastatin in a recently introduced combination tablet." | 2.42 | Extended-release niacin for modifying the lipoprotein profile. ( Guyton, JR, 2004) |
| "Treatment of the dyslipidemia associated with type 2 diabetes and FCHL with a combination of a statin and a thiazolidinedione or niacin offers the most comprehensive modality to correct the various lipid abnormalities." | 2.42 | Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. ( Ayyobi, AF; Brunzell, JD, 2003) |
| "However, many patients with dyslipidemia who have or are at risk for CHD do not reach target LDL-C goals." | 2.42 | Therapy to reduce risk of coronary heart disease. ( Rader, DJ, 2003) |
| "Patients with dyslipidemias continue to be undertreated in both the primary and secondary prevention settings." | 2.42 | Combination therapy in the management of complex dyslipidemias. ( Davidson, MH; Toth, PP, 2004) |
| "Niacin has multifarious lipoprotein and anti-atherothrombosis effects that improve endothelial function, reduce inflammation, increase plaque stability, and diminish thrombosis." | 2.42 | Antiatherothrombotic effects of nicotinic acid. ( Rosenson, RS, 2003) |
| "Niacin is an inexpensive drug useful in treating various forms of hyperlipidemia." | 2.41 | Use of niacin in the prevention and management of hyperlipidemia. ( Arnold, G; Robinson, AW; Sloan, HL, 2001) |
| " In addition, there have been preclinical reports suggesting the potential usefulness of orally bioavailable inhibitors of cholesterol ester transfer protein in plasma and of acylcoA:cholesterol acyltransferase in monocyte-macrophages." | 2.41 | Novel lipid-regulating drugs. ( Naoumova, RP; Thompson, GR, 2000) |
| "The characteristic dyslipidemia of insulin resistance consists of elevated triglyceride and triglyceride-rich lipoprotein levels, low levels of high-density lipoprotein cholesterol, and increased concentrations of small, dense low-density lipoprotein cholesterol." | 2.41 | Pathophysiology and treatment of the dyslipidemia of insulin resistance. ( Capuzzi , DM; Cohn, G; Valdes, G, 2001) |
| " These issues of possible harm or lack of benefit from long-term use of lipid-lowering therapy, and cost effectiveness, are also pertinent in the pediatric setting." | 2.41 | Should pediatric patients with hyperlipidemia receive drug therapy? ( Bhatnagar, D, 2002) |
| "Patients with combined dyslipidemia are at high risk for coronary artery disease and often require combination drug therapy to achieve lipid levels recommended by the US National Cholesterol Education Program's third Adult Treatment Panel (ATP III)." | 2.41 | Combination therapy for combined dyslipidemia. ( Ballantyne, CM; Xydakis, AM, 2002) |
| "Niacin is an important therapeutic option for the treatment of dyslipidemias and is the only agent currently available that favorably affects all components of the lipid profile to a significant degree." | 2.41 | Understanding niacin formulations. ( Pieper, JA, 2002) |
| "Combination therapy for hyperlipidemia, especially combined hyperlipidemia, may have advantages over single drug therapy, affording better improvement in lipoprotein risk factors and possibly better prevention of atherothrombotic events." | 2.40 | Combination drug therapy for combined hyperlipidemia. ( Guyton, JR, 1999) |
| "The niacin-statin treatment regimens gave augmented low-density lipoprotein (LDL)-cholesterol reduction along with favorable changes in high-density lipoprotein (HDL) cholesterol, lipoprotein(a), and triglycerides." | 2.40 | Treatment of hyperlipidemia with combined niacin-statin regimens. ( Capuzzi, DM; Guyton, JR, 1998) |
| "Treatment of dyslipidemia to prevent CHD depends on the pattern and severity of dyslipidemia, the presence of overt CHD, and the patient's response to diet." | 2.40 | Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease. ( Borgia, MC; Medici, F, 1998) |
| "Effective treatment of dyslipidemia improves prognosis." | 2.40 | Combination drug therapy for dyslipidemia. ( Alaswad, K; Moe, RM; O'Keefe, JH, 1999) |
| "Niacin can be very effective and safe in lowering low-density lipoprotein cholesterol and triglyceride levels and also in increasing high-density lipoprotein cholesterol levels." | 2.39 | Niacin for lipid disorders. Indications, effectiveness, and safety. ( Brown, WV, 1995) |
| "Several forms of dyslipidemia are associated with premature coronary artery disease (CAD) and other vascular disease." | 2.39 | Hyperlipidemia: perspectives in diagnosis and treatment. ( Gotto, AM; Yeshurun, D, 1995) |
| "Recent studies suggest that treating dyslipidemia in persons with coronary atherosclerosis may decrease morbidity and mortality." | 2.39 | Number-needed-to-treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy. ( Rembold, CM, 1996) |
| "Niacin has a long history of use as a lipid lowering agent and has several attractive features." | 2.39 | New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug. ( Crouse, JR, 1996) |
| " Careful dosing titration may, however, minimize these effects." | 2.37 | Nicotinic acid: a review of its clinical use in the treatment of lipid disorders. ( Figge, HL; Figge, J; Mutnick, AH; Sacks, F; Souney, PF, 1988) |
| "Hyperlipidemia should be managed systematically using information about the association between increased lipid concentrations and CAD, patient risk factors, and limitations of both diet and drug therapy." | 2.37 | Contemporary recommendations for evaluating and treating hyperlipidemia. ( Perry, RS, 1986) |
| "The Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trial found higher incidence rates of adverse reactions, including bleeding, in patients receiving the combination of extended-release niacin and laropiprant versus placebo." | 1.48 | Safety assessment of niacin in the US Food and Drug Administration's mini-sentinel system. ( Gagne, JJ; Hampp, C; Houstoun, M; Marshall, JH; Reichman, ME; Toh, S, 2018) |
| "Hyperlipidemia treatment based on niacin requires gastrointestinal administration of relatively high doses." | 1.42 | The use of a hydrogel matrix for controlled delivery of niacin to the gastrointestinal tract for treatment of hyperlipidemia. ( Hobzova, R; Hrib, J; Hromadka, R; Michalek, J; Sandrikova, V; Sirc, J; Slanar, O; Stankova, B; Vetrik, M; Zak, A, 2015) |
| "High-fat diet induced hyperlipidemia and obesity in immature rats." | 1.39 | [Relationship of ox-LDL/LOX-1 and vascular endothelial dysfunction of diet-induced obese immature rats and nicotinic acid's intervention outcomes]. ( Han, B; Niu, N; Sun, SZ; Wang, Y, 2013) |
| "Multiple-drug therapy of dyslipidemia is frequently used to achieve treatment goals in high-risk patients with coronary artery disease." | 1.36 | LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol. ( Phillips, W; Schaefer, S, 2010) |
| "Niacin is a unique lipid-lowering medication with a capacity to lower low-density lipoprotein cholesterol (LDL-c), triglyceride and increase HDL-c." | 1.36 | What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease? ( Ahmed, MH, 2010) |
| " Treatment with prolonged-release nicotinic acid was initiated according to the approved dosing regimen." | 1.35 | [Use of prolonged-release nicotinic acid in patients treated with statins as a secondary prevention and a persistently low HDL-cholesterol level in France]. ( Mosnier, M; Paillard, F, 2008) |
| " Since DDIs are associated with adverse reactions, we performed a cross-sectional study to assess the prevalence of potentially critical drug-drug and drug-statin interactions in an outpatient adult population with dyslipidaemia." | 1.33 | Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. ( Hess, L; Krähenbühl, S; Krähenbühl-Melcher, A; Rätz Bravo, AE; Schlienger, RG; Tchambaz, L, 2005) |
| "Niacin has been used for decades for the treatment of dyslipidemia because of its favorable effects on all lipoprotein parameters." | 1.32 | Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. ( Pieper, JA, 2003) |
| "Also dyslipidemia seems to be involved in enzyme activity variations of the tryptophan metabolism along the kynurenine pathway." | 1.31 | Enzyme activities along the tryptophan-nicotinic acid pathway in alloxan diabetic rabbits. ( Allegri, G; Bertazzo, A; Biasiolo, M; Caparrotta, L; Costa, CV; Ragazzi, E, 2002) |
| " Because a slow-release matrix tablet of the drug combination resulted in a similar magnitude of effect as the IGI administration, the present study provides a pharmacodynamic rationale for the use of a slow-release low-dose niacin-bezafibrate combination." | 1.31 | Pharmacodynamic effects of bezafibrate and niacin combination: implications of the mode of administration. ( Friedman, M; Haimov, T; Hoffman, A; Lomnicky, Y; Luria, MH, 2000) |
| "Niaspan, when added to a stable dose of a statin in 66 subjects, was found to be safe and highly effective in improving lipid parameters." | 1.31 | Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. ( Bansavich, LL; Friedrich, CA; Meagher, E; Mohler, ER; Rader, DJ; Ross, JL; Vartanian, SF; Wolfe, ML, 2001) |
| " Successful and safe therapy requires ongoing supervision and instruction by qualified health care providers to monitor the efficacy of therapy and minimize niacin's potential for adverse effects." | 1.30 | ASHP Therapeutic Position Statement on the safe use of niacin in the management of dyslipidemias. American Society of Health-System Pharmacists. ( , 1997) |
| "13 patients aged 39 to 60 years with coronary atherosclerosis confirmed at selective coronary angiography combined with primary hyperlipidemia (phenotypes 2a and 2b) received enduracin in a dose 1500 mg/day." | 1.30 | [The effect of long-term Enduracin monotherapy on the clinical and biochemical status of patients with ischemic heart disease]. ( Aronskaia, EE; Kukharchuk, VV; Malyshev, PP; Rozhkova, TA; Semenova, OA; Solov'ev, EIu, 1997) |
| "Niacin use was associated with a 16." | 1.30 | Relative effectiveness of niacin and lovastatin for treatment of dyslipidemias in a health maintenance organization. ( O'Connor, PJ; Rush, WA; Trence, DL, 1997) |
| "Bezafibrate was effective hypolipidemic agent in normal rats, but addition of nicotinic acid has certainly improved the effectiveness further which could be of clinical significance." | 1.28 | Effect of bezafibrate & nicotinic acid on triton induced hyperlipidemias in CFY rats. ( Krishnamurthy, A; Thapar, GS, 1991) |
| " This manifestation of hepatotoxicity seems to differ from that previously reported in association with use of crystalline niacin, which occurred with high dosage and prolonged usage of the medication." | 1.28 | Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. ( Allison, TG; Etchason, JA; Gau, GT; Kottke, BA; Marttila, JK; Miller, TD; Squires, RW, 1991) |
| " Most of these drugs have side effects which, in the elderly, may necessitate lower dosing than usual." | 1.27 | Treating hyperlipidemia, Part III: Drug therapy. ( Brown, WV; Karmally, W; Smith, DA, 1987) |
| "Experimental hyperlipidemia was induced in ddY, C57BL, BALB and ICR strain mice and in Wistar rats." | 1.27 | [Strains and species differences in experimental hyperlipidemia]. ( Hirai, Y; Kawakami, M; Koyama, S; Mishima, Y; Mizutani, A; Morishita, S; Saito, T, 1986) |
| "Probucol has a sustained effect, additive to that of a lipid-lowering diet; it can reduce total serum cholesterol and cause xanthoma regression even in patients with receptor-defective homozygous familial hypercholesterolemia." | 1.27 | Medical management of hyperlipidemia and the role of probucol. ( Davignon, J, 1986) |
| " Adverse side effects ranging from mere annoyances to uncommon serious consequences may be associated with dietary modification, recreational physical exercise, and drug intervention." | 1.27 | Adverse effects of the treatment for hyperlipidemia. ( Malinow, MR, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 46 (15.38) | 18.7374 |
| 1990's | 67 (22.41) | 18.2507 |
| 2000's | 145 (48.49) | 29.6817 |
| 2010's | 40 (13.38) | 24.3611 |
| 2020's | 1 (0.33) | 2.80 |
| Authors | Studies |
|---|---|
| Wise, A | 1 |
| Foord, SM | 1 |
| Fraser, NJ | 1 |
| Barnes, AA | 1 |
| Elshourbagy, N | 1 |
| Eilert, M | 1 |
| Ignar, DM | 1 |
| Murdock, PR | 1 |
| Steplewski, K | 1 |
| Green, A | 1 |
| Brown, AJ | 1 |
| Dowell, SJ | 1 |
| Szekeres, PG | 1 |
| Hassall, DG | 1 |
| Marshall, FH | 1 |
| Wilson, S | 1 |
| Pike, NB | 1 |
| Mathew, RO | 1 |
| Rosenson, RS | 6 |
| Lyubarova, R | 1 |
| Chaudhry, R | 1 |
| Costa, SP | 1 |
| Bangalore, S | 1 |
| Sidhu, MS | 1 |
| Skolnik, N | 1 |
| Jaffa, FM | 1 |
| Kalyani, RR | 1 |
| Johnson, E | 1 |
| Shubrook, JH | 1 |
| Ferchaud-Roucher, V | 1 |
| Croyal, M | 1 |
| Moyon, T | 1 |
| Zair, Y | 1 |
| Krempf, M | 1 |
| Ouguerram, K | 1 |
| Gagne, JJ | 1 |
| Houstoun, M | 1 |
| Reichman, ME | 1 |
| Hampp, C | 1 |
| Marshall, JH | 1 |
| Toh, S | 1 |
| Xie, YD | 1 |
| Chen, ZZ | 1 |
| Li, N | 1 |
| Lu, WF | 1 |
| Xu, YH | 1 |
| Lin, YY | 1 |
| Shao, LH | 1 |
| Wang, QT | 1 |
| Guo, LY | 1 |
| Gao, YQ | 1 |
| Yang, GD | 1 |
| Li, YP | 1 |
| Bian, XL | 1 |
| Cai, S | 1 |
| Liu, TYA | 1 |
| Arevalo, JF | 1 |
| Nicholls, SJ | 1 |
| Andrews, J | 1 |
| Duong, M | 1 |
| Gillard, BK | 1 |
| Raya, JL | 1 |
| Ruiz-Esponda, R | 1 |
| Iyer, D | 1 |
| Coraza, I | 1 |
| Balasubramanyam, A | 2 |
| Pownall, HJ | 2 |
| Nofer, JR | 1 |
| Le, NA | 1 |
| Jin, R | 1 |
| Tomassini, JE | 4 |
| Tershakovec, AM | 4 |
| Neff, DR | 1 |
| Wilson, PW | 1 |
| Niu, N | 2 |
| Sun, SZ | 1 |
| Han, B | 1 |
| Wang, Y | 2 |
| Zafrir, B | 1 |
| Jain, M | 1 |
| Nesan, D | 1 |
| Ng, DS | 2 |
| Heemskerk, MM | 1 |
| Dharuri, HK | 1 |
| van den Berg, SA | 1 |
| Jónasdóttir, HS | 1 |
| Kloos, DP | 1 |
| Giera, M | 1 |
| van Dijk, KW | 1 |
| van Harmelen, V | 1 |
| Zeman, M | 3 |
| Vecka, M | 3 |
| Perlík, F | 2 |
| Hromádka, R | 3 |
| Staňková, B | 3 |
| Tvrzická, E | 3 |
| Žák, A | 4 |
| Sirc, J | 2 |
| Hrib, J | 2 |
| Vetrik, M | 1 |
| Hobzova, R | 1 |
| Slanar, O | 1 |
| Sandrikova, V | 1 |
| Michalek, J | 1 |
| Bittner, V | 1 |
| Deng, L | 1 |
| Taylor, B | 1 |
| Glasser, SP | 1 |
| Kent, ST | 1 |
| Farkouh, ME | 1 |
| Muntner, P | 1 |
| la Paz, SM | 1 |
| Bermudez, B | 1 |
| Naranjo, MC | 1 |
| Lopez, S | 1 |
| Abia, R | 1 |
| Muriana, FJ | 1 |
| Rahimy, E | 1 |
| Gaynon, MW | 1 |
| Paulus, YM | 1 |
| Alexander, JL | 1 |
| Mansour, SE | 1 |
| Brinton, EA | 1 |
| Triscari, J | 1 |
| Brudi, P | 1 |
| Chen, E | 2 |
| Johnson-Levonas, AO | 1 |
| Sisk, CM | 2 |
| Ruck, RA | 1 |
| MacLean, AA | 1 |
| Maccubbin, D | 2 |
| Mitchel, YB | 1 |
| Lamon-Fava, S | 1 |
| Diffenderfer, MR | 1 |
| Barrett, PH | 1 |
| Buchsbaum, A | 1 |
| Nyaku, M | 1 |
| Horvath, KV | 1 |
| Asztalos, BF | 1 |
| Otokozawa, S | 1 |
| Ai, M | 1 |
| Matthan, NR | 1 |
| Lichtenstein, AH | 1 |
| Dolnikowski, GG | 1 |
| Schaefer, EJ | 2 |
| Svilaas, A | 1 |
| Strandberg, T | 1 |
| Eriksson, M | 1 |
| Hildebrandt, P | 1 |
| Westheim, A | 1 |
| Yu, YH | 1 |
| Wang, LJ | 1 |
| Li, Q | 1 |
| Guo, LM | 1 |
| Robinson, JG | 1 |
| Guthrie, R | 1 |
| Ansell, BJ | 2 |
| Jones, PH | 4 |
| Xenoulis, PG | 1 |
| Steiner, JM | 1 |
| Hou, R | 1 |
| Goldberg, AC | 3 |
| Kole, LA | 1 |
| Fazio, S | 3 |
| Guyton, JR | 9 |
| Polis, AB | 1 |
| Adewale, AJ | 2 |
| Ryan, NW | 1 |
| Phillips, W | 1 |
| Schaefer, S | 1 |
| Choudhury, RP | 1 |
| Virani, SS | 1 |
| Ballantyne, CM | 4 |
| Ahmed, MH | 1 |
| Lin, J | 1 |
| Shah, A | 2 |
| Kamerath, JH | 1 |
| De Luigi, AJ | 1 |
| Döger, MM | 6 |
| Sokmen, BB | 2 |
| Yanardag, R | 6 |
| Insull, W | 1 |
| Toth, PP | 2 |
| Superko, HR | 2 |
| Thakkar, RB | 1 |
| Krause, S | 1 |
| Jiang, P | 1 |
| Parreno, RA | 1 |
| Padley, RJ | 1 |
| Qandil, AM | 1 |
| Rezigue, MM | 1 |
| Tashtoush, BM | 1 |
| Chen, F | 1 |
| Yan, L | 1 |
| Sirah, W | 1 |
| Davidson, M | 2 |
| Blomqvist, P | 1 |
| McKenney, JM | 3 |
| Jensen, E | 1 |
| Shah, MK | 1 |
| Critchley, WR | 1 |
| Yonan, N | 1 |
| Williams, SG | 1 |
| Shaw, SM | 1 |
| Julius, U | 1 |
| Fischer, S | 1 |
| Grundy, SM | 6 |
| Vega, GL | 3 |
| McGovern, ME | 5 |
| Tulloch, BR | 1 |
| Kendall, DM | 1 |
| Fitz-Patrick, D | 1 |
| Ganda, OP | 1 |
| Buse, JB | 1 |
| Robertson, DD | 1 |
| Sheehan, JP | 1 |
| Pieper, JA | 3 |
| Ito, MK | 4 |
| Barter, P | 1 |
| Packard, C | 1 |
| Olsson, AG | 2 |
| Stone, NJ | 2 |
| McKenney, J | 3 |
| Xydakis, AM | 2 |
| Bays, H | 1 |
| Brown, AS | 1 |
| Davidson, MH | 4 |
| Moon, YS | 1 |
| Kashyap, ML | 5 |
| Duvall, WL | 1 |
| Blazing, MA | 1 |
| Saxena, S | 1 |
| Stein, EA | 2 |
| Yim, BT | 1 |
| Chong, PH | 1 |
| Rader, DJ | 2 |
| Mikhail, N | 1 |
| Bays, HE | 4 |
| Dujovne, CA | 1 |
| White, TE | 1 |
| Hutcheson, AG | 1 |
| Crouse, JR | 2 |
| Hunninghake, DB | 2 |
| Koren, M | 2 |
| Brazg, R | 1 |
| Murdock, D | 1 |
| Weiss, S | 2 |
| Pearson, T | 1 |
| Capuzzi, DM | 6 |
| Morgan, JM | 5 |
| Weiss, RJ | 1 |
| Chitra, RR | 1 |
| Hutchinson, HG | 1 |
| Cressman, MD | 2 |
| Kastelein, J | 1 |
| Ryan, MJ | 1 |
| Gibson, J | 1 |
| Simmons, P | 1 |
| Stanek, E | 1 |
| Cottrell, DA | 1 |
| Marshall, BJ | 1 |
| Falko, JM | 1 |
| Talbert, RL | 2 |
| Miller, M | 1 |
| Ayyobi, AF | 1 |
| Brunzell, JD | 3 |
| BELLE, M | 1 |
| HALPERN, MM | 1 |
| DAVIS, OF | 1 |
| BECK, C | 1 |
| BERGAL, M | 1 |
| SLOAN, N | 1 |
| LEVINE, AJ | 1 |
| HOLLOMAN, JL | 1 |
| DAVIS, CC | 1 |
| LEEPER, LC | 1 |
| TRIBIANO, CW | 1 |
| SPENCER, JL | 1 |
| WADDELL, WR | 1 |
| HURLEY, N | 1 |
| FIELD, RA | 1 |
| KNUECHEL, F | 1 |
| FITZGERALD, O | 1 |
| HEFFERNAN, A | 1 |
| BRENNAN, P | 1 |
| MULCAHY, R | 1 |
| FENNELLY, JJ | 1 |
| MCFARLANE, R | 1 |
| FAIVRE, G | 1 |
| GILGENKRANTZ, JM | 1 |
| CHERRIER, F | 1 |
| HENRY, C | 1 |
| YASUGI, T | 1 |
| SCHOEN, H | 4 |
| ZELLER, W | 2 |
| HENNING, N | 1 |
| ILIESCU, M | 1 |
| DOMOCOS, G | 1 |
| IACOBINI, P | 1 |
| CONSTANTINESCU, S | 1 |
| ILIESCU, CC | 1 |
| NEUMANN, J | 1 |
| STUETTGEN, G | 1 |
| LEUTIGER, H | 1 |
| WENNERBY, S | 1 |
| VASTESAEGER, MM | 1 |
| CALI, G | 1 |
| PIETROPAOLO, C | 1 |
| FIORENTINO, E | 1 |
| AURITI, R | 1 |
| BODE, G | 1 |
| GRIMM, B | 1 |
| Thompson, PD | 1 |
| Kolovou, GD | 1 |
| Daskalova, DC | 1 |
| Petropoulos, II | 1 |
| Anagnostopoulou, KK | 1 |
| Bilianou, HI | 1 |
| Pilatis, ND | 1 |
| Pavlidis, AN | 1 |
| Cokkinos, DV | 1 |
| Meyers, CD | 1 |
| Carr, MC | 1 |
| Park, S | 1 |
| Dib, JG | 1 |
| Dedeyan, S | 1 |
| Dierkes, J | 1 |
| Westphal, S | 2 |
| Luley, C | 2 |
| Malik, S | 1 |
| Streja, D | 1 |
| Mal', GS | 1 |
| Rubenfire, M | 1 |
| Gerber, MT | 1 |
| Mondy, KE | 1 |
| Yarasheski, KE | 1 |
| Drechsler, H | 1 |
| Claxton, S | 1 |
| Stoneman, J | 1 |
| DeMarco, D | 1 |
| Powderly, WG | 1 |
| Tebas, P | 1 |
| Carlson, LA | 3 |
| Ascaso, JF | 1 |
| Fernández-Cruz, A | 1 |
| González Santos, P | 1 |
| Hernández Mijares, A | 1 |
| Mangas Rojas, A | 1 |
| Millán, J | 1 |
| Felipe Pallardo, L | 1 |
| Pedro-Botet, J | 1 |
| Pérez-Jiménez, F | 1 |
| Pía, G | 1 |
| Pintó, X | 1 |
| Plaza, I | 1 |
| Rubiés-Prat, J | 1 |
| Nicholls, S | 1 |
| Lundman, P | 1 |
| Meagher, EA | 1 |
| Carey, CM | 2 |
| Intenzo, C | 1 |
| Tulenko, T | 1 |
| Kearney, D | 1 |
| Walker, K | 1 |
| Lincoff, A | 1 |
| Bolkent, S | 4 |
| Benz, R | 1 |
| Suter, PM | 1 |
| Berra, K | 2 |
| Backes, JM | 1 |
| Gibson, CA | 1 |
| Rätz Bravo, AE | 1 |
| Tchambaz, L | 1 |
| Krähenbühl-Melcher, A | 1 |
| Hess, L | 1 |
| Schlienger, RG | 1 |
| Krähenbühl, S | 1 |
| Asano, M | 1 |
| Yamada, N | 1 |
| Foley, SM | 1 |
| Peksel, A | 2 |
| Yesilyaprak, B | 1 |
| Arisan-Atac, I | 1 |
| Wieneke, H | 1 |
| Schmermund, A | 1 |
| Erbel, R | 1 |
| Reasner, CA | 1 |
| Cater, NB | 1 |
| Meguro, S | 1 |
| Shepherd, J | 3 |
| Betteridge, J | 1 |
| Van Gaal, L | 1 |
| Ragazzi, E | 2 |
| Costa, CV | 2 |
| Comai, S | 1 |
| Bertazzo, A | 2 |
| Caparrotta, L | 2 |
| Allegri, G | 2 |
| Parhofer, KG | 1 |
| Ducobu, J | 1 |
| Balbisi, EA | 1 |
| Accinni, R | 1 |
| Rosina, M | 1 |
| Bamonti, F | 1 |
| Della Noce, C | 1 |
| Tonini, A | 1 |
| Bernacchi, F | 1 |
| Campolo, J | 1 |
| Caruso, R | 1 |
| Novembrino, C | 1 |
| Ghersi, L | 1 |
| Lonati, S | 1 |
| Grossi, S | 1 |
| Ippolito, S | 1 |
| Lorenzano, E | 1 |
| Ciani, A | 1 |
| Gorini, M | 1 |
| Samson, SL | 1 |
| Scott, LW | 2 |
| Smith, EO | 1 |
| Sekhar, RV | 1 |
| Atac, IA | 1 |
| Bilen, ZG | 1 |
| Borucki, K | 1 |
| Taneva, E | 1 |
| Makarova, R | 1 |
| Inceli, MS | 1 |
| Li, XP | 1 |
| Duan, J | 1 |
| Zhao, SP | 2 |
| Tan, MY | 1 |
| Xu, ZM | 1 |
| Zhang, DQ | 1 |
| Yuvaraj, S | 1 |
| Premkumar, VG | 1 |
| Vijayasarathy, K | 1 |
| Gangadaran, SG | 1 |
| Sachdanandam, P | 1 |
| Broncel, M | 1 |
| Balcerak, M | 1 |
| Chojnowska-Jezierska, J | 2 |
| Nagalski, A | 1 |
| Bryła, J | 1 |
| Sanyal, S | 1 |
| Karas, RH | 1 |
| Kuvin, JT | 1 |
| Gille, A | 1 |
| Bodor, ET | 1 |
| Ahmed, K | 1 |
| Offermanns, S | 1 |
| Athyros, VG | 1 |
| Tziomalos, K | 1 |
| Mikhailidis, DP | 1 |
| Pagourelias, ED | 1 |
| Kakafika, AI | 1 |
| Skaperdas, A | 1 |
| Hatzitolios, A | 1 |
| Karagiannis, A | 1 |
| Suren Castillo, S | 1 |
| Bouknight, P | 1 |
| Mackler, L | 1 |
| Heffington, M | 1 |
| Yang, J | 1 |
| Li, J | 1 |
| Wu, ZH | 1 |
| Dong, SZ | 1 |
| Drexel, H | 1 |
| Aronow, WS | 1 |
| Nampurath, GK | 1 |
| Mathew, SP | 1 |
| Khanna, V | 1 |
| Zachariah, RT | 1 |
| Kanji, S | 1 |
| Chamallamudi, MR | 1 |
| Restrepo Valencia, CA | 1 |
| Cruz, J | 1 |
| Knopp, RH | 6 |
| Paramsothy, P | 1 |
| Atkinson, B | 1 |
| Dowdy, A | 2 |
| Brown, BG | 3 |
| Zhao, XQ | 2 |
| Paillard, F | 1 |
| Mosnier, M | 1 |
| Blankenhorn, DH | 1 |
| Azen, SP | 1 |
| Nessim, SA | 1 |
| Pyrig, LA | 1 |
| Petrun, NM | 1 |
| Nikulina, GG | 1 |
| Gorelova, NR | 1 |
| Nash, DT | 1 |
| Smith, SR | 1 |
| Havel, RJ | 1 |
| Kane, JP | 2 |
| Gustafsson, K | 1 |
| Kiessling, H | 1 |
| Gibbons, LW | 1 |
| Gonzalez, V | 1 |
| Gordon, N | 1 |
| Grundy, S | 1 |
| Tsalamandris, C | 1 |
| Panagiotopoulos, S | 1 |
| Sinha, A | 1 |
| Cooper, ME | 1 |
| Jerums, G | 1 |
| Brown, WV | 2 |
| Lal, SM | 1 |
| Hewett, JE | 1 |
| Petroski, GF | 1 |
| Van Stone, JC | 1 |
| Ross, G | 1 |
| Yeshurun, D | 1 |
| Gotto, AM | 4 |
| Shakir, KM | 1 |
| Kroll, S | 1 |
| Aprill, BS | 1 |
| Drake, AJ | 1 |
| Eisold, JF | 1 |
| Morales, E | 1 |
| Spinler, SA | 1 |
| Wilson, MD | 1 |
| Chin, MM | 1 |
| Jozefiak, E | 1 |
| Fraunfelder, FW | 1 |
| Fraunfelder, FT | 1 |
| Illingworth, DR | 2 |
| Gharavi, AG | 1 |
| Diamond, JA | 1 |
| Smith, DA | 2 |
| Phillips, RA | 1 |
| Kreisberg, RA | 1 |
| Kuo, PT | 1 |
| Felicetta, JV | 1 |
| Seed, M | 1 |
| O'Connor, B | 1 |
| Perombelon, N | 1 |
| O'Donnell, M | 1 |
| Reaveley, D | 1 |
| Knight, BL | 1 |
| Wahlberg, G | 2 |
| Walldius, G | 2 |
| Rembold, CM | 1 |
| Mann, WA | 1 |
| Windler, E | 1 |
| Beil, FU | 1 |
| Greten, H | 1 |
| Spencer, GA | 1 |
| Wirebaugh, S | 1 |
| Whitney, EJ | 2 |
| Schiel, R | 1 |
| Bambauer, R | 1 |
| Müller, UA | 1 |
| Farmer, JA | 1 |
| Aronov, DM | 1 |
| O'Connor, PJ | 1 |
| Rush, WA | 1 |
| Trence, DL | 1 |
| Mostaza, JM | 1 |
| Schulz, I | 1 |
| Bardsley, J | 1 |
| Poulin, D | 1 |
| Hillger, LA | 1 |
| Maher, VM | 1 |
| Albers, JJ | 2 |
| Andrews, TC | 1 |
| Green, G | 1 |
| Kalenian, R | 1 |
| Personius, BE | 1 |
| Kukharchuk, VV | 1 |
| Solov'ev, EIu | 1 |
| Malyshev, PP | 1 |
| Rozhkova, TA | 1 |
| Semenova, OA | 1 |
| Aronskaia, EE | 1 |
| Schuna, AA | 1 |
| McCormick, LS | 2 |
| Kafonek, S | 1 |
| Black, DM | 2 |
| Borgia, MC | 1 |
| Medici, F | 1 |
| Adamska-Dyniewska, H | 1 |
| Krause, BR | 1 |
| Princen, HM | 1 |
| Alagona, P | 2 |
| Kafonek, SD | 1 |
| Kashyap, M | 1 |
| Sprecher, D | 1 |
| Jenkins, S | 1 |
| Marcovina, S | 1 |
| Leighton, RF | 1 |
| Gordon, NF | 1 |
| Small, GS | 1 |
| Davis, WJ | 1 |
| Ward, ES | 1 |
| Lomnicky, Y | 2 |
| Friedman, M | 2 |
| Luria, MH | 2 |
| Raz, I | 1 |
| Hoffman, A | 2 |
| Smolenskaia, OG | 1 |
| Kazakov, IaE | 1 |
| Barats, SS | 1 |
| Gylys, KH | 1 |
| Sikand, G | 1 |
| Wong, ND | 1 |
| Hsu, JC | 1 |
| Goldberg, A | 1 |
| Guyton, J | 1 |
| Rodgers, J | 1 |
| Sachson, R | 1 |
| Samuel, P | 1 |
| Haimov, T | 1 |
| McCarty, MF | 1 |
| Thompson, GR | 1 |
| Naoumova, RP | 1 |
| Alaswad, K | 1 |
| O'Keefe, JH | 1 |
| Moe, RM | 1 |
| Zambon, A | 1 |
| Deeb, SS | 1 |
| Hokanson, JE | 1 |
| Sposito, AC | 1 |
| Mansur, AP | 1 |
| Maranhão, RC | 1 |
| Rodrigues-Sobrinho, CR | 1 |
| Coelho, OR | 1 |
| Ramires, JA | 1 |
| Wolfe, ML | 1 |
| Vartanian, SF | 1 |
| Ross, JL | 1 |
| Bansavich, LL | 1 |
| Mohler, ER | 1 |
| Meagher, E | 1 |
| Friedrich, CA | 1 |
| Cía Gómez, P | 1 |
| Robinson, AW | 1 |
| Sloan, HL | 1 |
| Arnold, G | 1 |
| Onuma, T | 1 |
| Kawamori, R | 1 |
| Ogaki, S | 1 |
| Matsushima, T | 1 |
| Legato, MJ | 1 |
| Pearson, TA | 1 |
| Smith, SC | 1 |
| Watkins, ML | 1 |
| Jacobson, TA | 1 |
| Cohn, G | 1 |
| Valdes, G | 1 |
| Capuzzi , DM | 1 |
| Busquets, S | 1 |
| Carbó, N | 1 |
| Almendro, V | 1 |
| Figueras, M | 1 |
| López-Soriano, FJ | 1 |
| Argilés, JM | 1 |
| Taher, TH | 1 |
| Dzavik, V | 1 |
| Reteff, EM | 1 |
| Pearson, GJ | 1 |
| Woloschuk, BL | 1 |
| Francis, GA | 1 |
| Wink, J | 1 |
| Giacoppe, G | 1 |
| King, J | 1 |
| Kwiterovich, PO | 1 |
| Harper, WL | 1 |
| Toth, PD | 1 |
| Favrot, LK | 1 |
| Kerzner, B | 1 |
| Nash, SD | 1 |
| Simmons, PD | 1 |
| Bhatnagar, D | 1 |
| Klungel, OH | 1 |
| Heckbert, SR | 1 |
| de Boer, A | 1 |
| Leufkens, HG | 1 |
| Sullivan, SD | 1 |
| Fishman, PA | 1 |
| Veenstra, DL | 1 |
| Psaty, BM | 1 |
| Biasiolo, M | 1 |
| Ruhn, G | 2 |
| Prihoda, JS | 1 |
| Bassler, TJ | 1 |
| Keenan, JM | 1 |
| Wenz, JB | 1 |
| Ripsin, CM | 1 |
| Huang, Z | 1 |
| McCaffrey, DJ | 1 |
| O'Kane, MJ | 1 |
| Trinick, TR | 1 |
| Tynan, MB | 1 |
| Trimble, ER | 1 |
| Nicholls, DP | 1 |
| Dalton, TA | 1 |
| Berry, RS | 1 |
| Steiner, G | 1 |
| Whelan, AM | 1 |
| Price, SO | 1 |
| Fowler, SF | 1 |
| Hainer, BL | 1 |
| Krishnamurthy, A | 1 |
| Thapar, GS | 1 |
| DiPalma, JR | 1 |
| Thayer, WS | 1 |
| Palumbo, PJ | 1 |
| Etchason, JA | 1 |
| Miller, TD | 1 |
| Squires, RW | 1 |
| Allison, TG | 1 |
| Gau, GT | 1 |
| Marttila, JK | 1 |
| Kottke, BA | 1 |
| Earthman, TP | 1 |
| Odom, L | 1 |
| Mullins, CA | 1 |
| Szamosi, A | 1 |
| Simpson, H | 1 |
| Williamson, CM | 1 |
| Pringle, S | 1 |
| MacLean, J | 1 |
| Lorimer, AR | 1 |
| Packard, CJ | 2 |
| Johansson, J | 1 |
| Erikson, U | 1 |
| Figge, HL | 1 |
| Figge, J | 1 |
| Souney, PF | 1 |
| Mutnick, AH | 1 |
| Sacks, F | 1 |
| Karmally, W | 1 |
| Olivier, P | 1 |
| Plancke, MO | 1 |
| Marzin, D | 1 |
| Clavey, V | 1 |
| Sauzieres, J | 1 |
| Fruchart, JC | 1 |
| Goldstein, MR | 1 |
| Malloy, MJ | 1 |
| Naito, HK | 1 |
| Morishita, S | 1 |
| Saito, T | 1 |
| Mishima, Y | 1 |
| Mizutani, A | 1 |
| Hirai, Y | 1 |
| Koyama, S | 1 |
| Kawakami, M | 1 |
| Davignon, J | 1 |
| Tikkanen, MJ | 1 |
| Nikkilä, EA | 1 |
| Perry, RS | 1 |
| Malinow, MR | 1 |
| Stuyt, PM | 1 |
| Noseda, G | 1 |
| Cohen, M | 1 |
| Ginsberg, J | 1 |
| Hoff, C | 1 |
| Ogilvie, JT | 1 |
| Warnick, GR | 1 |
| Burrows, E | 1 |
| Retzlaff, B | 1 |
| Poole, M | 1 |
| Postnikova, NV | 1 |
| Vasilenko, IuK | 1 |
| Cherevatyĭ, VS | 1 |
| Parker, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metabolic Effects of an 8 Week Niaspan Treatment in Patients With Abdominal Obesity and Mixed Dyslipidemia[NCT01216956] | 24 participants (Actual) | Interventional | 2006-09-30 | Completed | |||
| Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy[NCT00246376] | 221 participants (Actual) | Interventional | 2004-01-31 | Completed | |||
| Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) Co-Administered in Patients With Type IIa or Type IIb Hyperlipidemia[NCT00271817] | Phase 3 | 1,220 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK0524B Versus Atorvastatin in Patients With Mixed Hyperlipidemia[NCT00289900] | Phase 3 | 2,340 participants (Actual) | Interventional | 2006-01-24 | Completed | ||
| Randomized, Double-blind, Placebo-controlled Trial of Niaspan® in Patients With Overt Diabetic Nephropathy and Moderate Renal Impairment[NCT00108485] | Phase 3 | 9 participants (Actual) | Interventional | 2005-04-30 | Terminated (stopped due to Unable to recruit sufficient study subjects) | ||
| [NCT00006295] | 370 participants (Anticipated) | Observational | 2000-08-31 | Completed | |||
| Effects of Ezetimibe in Association With Statins on Postprandial Lipemia in Type 2 Diabetic Patients[NCT00699023] | Phase 4 | 13 participants (Anticipated) | Interventional | 2008-06-30 | Completed | ||
| A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction[NCT00203476] | Phase 4 | 30 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia[NCT00005313] | 450 participants (Actual) | Observational | 2001-04-30 | Completed | |||
| A Multicenter Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)[NCT01152073] | 79 participants (Actual) | Interventional | 2009-10-31 | Completed | |||
| The Effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg Plus 10 mg Ezetimibe on Low Density Lipoprotein (LDL)-Subfractions in Patients With Type 2 Diabetes[NCT01384058] | Phase 4 | 41 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| Group 1 - Usual Care | 37.1 |
| Group 2 - Diet/Exercise Only | 38.7 |
| Group 3 - Diet/Exercise + Fenofibrate | 40.7 |
| Group 4 - Diet/Exercise + Niacin | 41.8 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 44.8 |
non-HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| Group 1 - Usual Care | 162.2 |
| Group 2 - Diet/Exercise Only | 165.4 |
| Group 3 - Diet/Exercise + Fenofibrate | 145.8 |
| Group 4 - Diet/Exercise + Niacin | 154 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 137.1 |
Total cholesterol (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| Group 1 - Usual Care | 195.6 |
| Group 2 - Diet/Exercise Only | 200.1 |
| Group 3 - Diet/Exercise + Fenofibrate | 184 |
| Group 4 - Diet/Exercise + Niacin | 190.8 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 178.4 |
Total cholesterol : HDL-C ratio: Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | ratio (Mean) |
|---|---|
| Group 1 - Usual Care | 5.2 |
| Group 2 - Diet/Exercise Only | 5.1 |
| Group 3 - Diet/Exercise + Fenofibrate | 4.5 |
| Group 4 - Diet/Exercise + Niacin | 4.6 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 4 |
Triglycerides (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| Group 1 - Usual Care | 199 |
| Group 2 - Diet/Exercise Only | 216.9 |
| Group 3 - Diet/Exercise + Fenofibrate | 155.1 |
| Group 4 - Diet/Exercise + Niacin | 177.6 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 135.6 |
"Body cell mass (kg)~Fat mass (kg)" (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | kg (Mean) | |
|---|---|---|
| Body cell mass | Fat mass | |
| Group 1 - Usual Care | 59.6 | 36.8 |
| Group 2 - Diet/Exercise | 67.3 | 37.5 |
| Group 3 - Diet/Exercise + Fenofibrate | 66.6 | 35.8 |
| Group 4 - Diet/Exercise + Niacin | 67.1 | 37.7 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 68.2 | 36.2 |
Adiponectin (micrograms/ml) (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | micrograms/ml (Mean) | |||
|---|---|---|---|---|
| Fasting insulin | HOMA-IR | Insulin sensitvity index | Adiponectin | |
| Group 1 - Usual Care | 8.7 | 1.92 | 3.54 | 7.12 |
| Group 2 - Diet/Exercise Only | 6.7 | 1.38 | 4.95 | 6.04 |
| Group 3 - Diet/Exercise + Fenofibrate | 9.5 | 2.02 | 3.81 | 5.24 |
| Group 4 - Diet/Exercise + Niacin | 11.9 | 2.76 | 2.88 | 11.01 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 10.3 | 2.38 | 2.38 | 10.34 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 24 weeks - 24 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 24 weeks
| Intervention | Percent change (Mean) |
|---|---|
| Ezetimibe/Simvastatin | 8.1 |
| Ezetimibe/Simvastatin + Niacin | 30.2 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 64 weeks - 64 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 64 weeks
| Intervention | Percent change (Mean) |
|---|---|
| Ezetimibe/Simvastatin | 9.0 |
| Ezetimibe/Simvastatin + Niacin | 30.5 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 24 weeks - 24 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 24 weeks
| Intervention | Percent change (Mean) |
|---|---|
| Ezetimibe/Simvastatin | -53.5 |
| Ezetimibe/Simvastatin + Niacin | -58.5 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 64 weeks - 64 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 64 weeks
| Intervention | Percent change (Mean) |
|---|---|
| Ezetimibe/Simvastatin | -49.3 |
| Ezetimibe/Simvastatin + Niacin | -54.0 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change, from baseline in LDL-C after 24 weeks - 24 Week Measure Minus Baseline (NCT00271817)
Timeframe: Baseline and 24 Weeks
| Intervention | Percent change (Mean) |
|---|---|
| Niacin | -20.1 |
| Ezetimibe/Simvastatin + Niacin | -58.5 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 24 weeks
| Intervention | Percent change (Mean) |
|---|---|
| Ezetimibe/Simvastatin | -47.9 |
| Ezetimibe/Simvastatin + Niacin | -55.6 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 64 weeks - 64 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 64 weeks
| Intervention | Percent change (Mean) |
|---|---|
| Ezetimibe/Simvastatin | -45.1 |
| Ezetimibe/Simvastatin + Niacin | -52.4 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 24 weeks
| Intervention | Percent change (Mean) |
|---|---|
| Niacin | -22.0 |
| Ezetimibe/Simvastatin + Niacin | -55.6 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 24 weeks - 24 week measure minus baseline (NCT00271817)
Timeframe: baseline and 24 Weeks
| Intervention | Percent change (Median) |
|---|---|
| Ezetimibe/Simvastatin | 23.7 |
| Ezetimibe/Simvastatin + Niacin | -42.5 |
Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 64 weeks - 64 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 64 weeks
| Intervention | Percent change (Median) |
|---|---|
| Ezetimibe/Simvastatin | -26.8 |
| Ezetimibe/Simvastatin + Niacin | -44.5 |
Blood samples taken at baseline and after 12 weeks of treatment to determine the Apo A-I levels. The change from baseline at Week 12 was recorded. (NCT00289900)
Timeframe: Baseline and Week 12
| Intervention | Percentage change (Least Squares Mean) |
|---|---|
| MK-0524B 2g/20 mg | 10.7 |
| MK-0524B 2g/40mg | 8.2 |
| Atorvastatin 10 mg | 1.7 |
| Atorvastatin 20 mg | 0.4 |
| Atorvastatin 40 mg | -0.8 |
| Atorvastatin 80 mg | -2.5 |
Blood samples taken at baseline and after 12 weeks of treatment to determine the Apo B levels. The change from baseline at Week 12 was recorded. (NCT00289900)
Timeframe: Baseline and Week 12
| Intervention | Percentage change (Least Squares Mean) |
|---|---|
| MK-0524B 2g/20 mg | -36.1 |
| MK-0524B 2g/40mg | -38.0 |
| Atorvastatin 10 mg | -26.9 |
| Atorvastatin 20 mg | -32.8 |
| Atorvastatin 40 mg | -37.2 |
| Atorvastatin 80 mg | -38.3 |
Blood samples taken at baseline and after 12 weeks of treatment to determine the CRP levels. The change from baseline at Week 12 was recorded. (NCT00289900)
Timeframe: Baseline and Week 12
| Intervention | Percentage change (Median) |
|---|---|
| MK-0524B 2g/20 mg | -15.4 |
| MK-0524B 2g/40mg | -20.0 |
| Atorvastatin 10 mg | -19.5 |
| Atorvastatin 20 mg | -28.6 |
| Atorvastatin 40 mg | -33.3 |
| Atorvastatin 80 mg | -38.1 |
Blood samples taken at baseline and after 12 weeks of treatment to determine the HDL-C levels. The change from baseline at Week 12 was recorded. (NCT00289900)
Timeframe: Baseline and Week 12
| Intervention | Percentage change (Least Squares Mean) |
|---|---|
| MK-0524B 2g/20 mg | 26.9 |
| MK-0524B 2g/40mg | 26.6 |
| Atorvastatin 10 mg | 7.0 |
| Atorvastatin 20 mg | 5.3 |
| Atorvastatin 40 mg | 4.5 |
| Atorvastatin 80 mg | 3.6 |
Blood samples taken at baseline and after 12 weeks of treatment to determine the LDL-C levels. The change from baseline at Week 12 was recorded. (NCT00289900)
Timeframe: Baseline and Week 12
| Intervention | Percentage change (Least Squares Mean) |
|---|---|
| MK-0524B 2g/20 mg | -40.4 |
| MK-0524B 2g/40mg | -42.8 |
| Atorvastatin 10 mg | -33.6 |
| Atorvastatin 20 mg | -39.8 |
| Atorvastatin 40 mg | -45.6 |
| Atorvastatin 80 mg | -47.5 |
Blood samples taken at baseline and after 12 weeks of treatment to determine the Lp(a) levels. The change from baseline at Week 12 was recorded. (NCT00289900)
Timeframe: Baseline and Week 12
| Intervention | Percentage change (Median) |
|---|---|
| MK-0524B 2g/20 mg | -15.2 |
| MK-0524B 2g/40mg | -14.6 |
| Atorvastatin 10 mg | 0.0 |
| Atorvastatin 20 mg | 0.0 |
| Atorvastatin 40 mg | 7.8 |
| Atorvastatin 80 mg | 8.8 |
Blood samples taken at baseline and after 12 weeks of treatment to determine the non-HDL-C levels. The change from baseline at Week 12 was recorded. (NCT00289900)
Timeframe: Baseline and Week 12
| Intervention | Percentage change (Least Squares Mean) |
|---|---|
| MK-0524B 2g/20 mg | -40.4 |
| MK-0524B 2g/40mg | -42.2 |
| Atorvastatin 10 mg | -31.3 |
| Atorvastatin 20 mg | -36.8 |
| Atorvastatin 40 mg | -42.6 |
| Atorvastatin 80 mg | -44.6 |
Blood samples taken at baseline and after 12 weeks of treatment to determine the TC and HDL-C levels. The TC/HDL-C ratio was then calculated for baseline and Week 12 and the change from baseline at Week 12 was recorded. (NCT00289900)
Timeframe: Baseline and Week 12
| Intervention | Percentage change (Least Squares Mean) |
|---|---|
| MK-0524B 2g/20 mg | -41.0 |
| MK-0524B 2g/40mg | -42.3 |
| Atorvastatin 10 mg | -28.2 |
| Atorvastatin 20 mg | -31.5 |
| Atorvastatin 40 mg | -36.0 |
| Atorvastatin 80 mg | -36.7 |
Blood samples taken at baseline and after 12 weeks of treatment to determine the LDL-C and HDL-C levels. The LDL-C/HDL-C ratio was then calculated for baseline and Week 12 and the change from baseline at Week 12 was recorded. (NCT00289900)
Timeframe: Baseline and Week 12
| Intervention | Percentage Change (Least Squares Mean) |
|---|---|
| MK-0524B 2g/20 mg | -50.9 |
| MK-0524B 2g/40mg | -53.0 |
| Atorvastatin 10 mg | -37.6 |
| Atorvastatin 20 mg | -42.4 |
| Atorvastatin 40 mg | -47.9 |
| Atorvastatin 80 mg | -48.8 |
Blood samples taken at baseline and after 12 weeks of treatment to determine the TC levels. The change from baseline at Week 12 was recorded. (NCT00289900)
Timeframe: Baseline and Week 12
| Intervention | Percentage change (Least Squares Mean) |
|---|---|
| MK-0524B 2g/20 mg | -28.1 |
| MK-0524B 2g/40mg | -30.0 |
| Atorvastatin 10 mg | -24.6 |
| Atorvastatin 20 mg | -29.4 |
| Atorvastatin 40 mg | -34.2 |
| Atorvastatin 80 mg | -36.1 |
Blood samples taken at baseline and after 12 weeks of treatment to determine the TG levels. The change from baseline at Week 12 was recorded. (NCT00289900)
Timeframe: Baseline and Week 12
| Intervention | Percentage change (Median) |
|---|---|
| MK-0524B 2g/20 mg | -40.3 |
| MK-0524B 2g/40mg | -42.0 |
| Atorvastatin 10 mg | -21.9 |
| Atorvastatin 20 mg | -23.8 |
| Atorvastatin 40 mg | -30.4 |
| Atorvastatin 80 mg | -33.8 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A clinical AE was an AE reported as a result of a clinical examination or reported by the participant. (NCT00289900)
Timeframe: up to 14 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled) | 59.6 |
| Atorvastatin 10, 20, 40, or 80 mg (Pooled) | 45.9 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Hepatitis-related AEs were identified by a collective review using the following pre-specified set of preferred terms: cholestasis, hepatic necrosis, hepatocellular damage, cytolytic hepatitis, hepatitis, hepatomegaly, jaundice, hepatic failure, hepatitis cholestatic, jaundice cholestatic, hepatitis fulminant, hyperbilirubinaemia, jaundice hepatocellular, ocular icterus, yellow skin, hepatic function abnormal, acute hepatic failure, subacute hepatic failure, hepatitis acute, hepatitis toxic, hepatotoxicity, and mixed hepatocellular-cholestatic injury. (NCT00289900)
Timeframe: up to 14 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled) | 0.0 |
| Atorvastatin 10, 20, 40, or 80 mg (Pooled) | 0.1 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test. (NCT00289900)
Timeframe: up to 14 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled) | 5.2 |
| Atorvastatin 10, 20, 40, or 80 mg (Pooled) | 5.9 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A clinical AE was an AE reported as a result of a clinical examination or reported by the participant. Participants who were discontinued from the study due to a clinical AE were recorded. (NCT00289900)
Timeframe: up to 14 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled) | 16.5 |
| Atorvastatin 10, 20, 40, or 80 mg (Pooled) | 4.9 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test. Participants who were discontinued from the study due to a laboratory AE were recorded. (NCT00289900)
Timeframe: up to 14 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled) | 0.7 |
| Atorvastatin 10, 20, 40, or 80 mg (Pooled) | 0.7 |
Select serious adverse cardiovascular events and all-cause mortality that occurred during the treatment phase of the study were adjudicated by an expert committee external to the sponsor. Those events confirmed by the committee a cardiovascular events were recorded. (NCT00289900)
Timeframe: up to 14 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled) | 0.1 |
| Atorvastatin 10, 20, 40, or 80 mg (Pooled) | 0.2 |
Participants had CK assessed throughout the 24 week treatment period. Participants who had any CK level that was >=10 x ULN and had associated muscle symptoms present within +/- 7 days were recorded. The UNLs for males and females were 207 U/L and 169 U/L, respectively. (NCT00289900)
Timeframe: up to 12 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled) | 0.1 |
| Atorvastatin 10, 20, 40, or 80 mg (Pooled) | 0.0 |
Participants had CK assessed throughout the 12 week treatment period. Participants who had any CK level that was >=10 x ULN and had associated muscle symptoms present within +/- 7 days that were reported as at least possibly related to study drug were recorded. The UNLs for males and females were 207 U/L and 169 U/L, respectively. (NCT00289900)
Timeframe: up to 12 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled) | 0.1 |
| Atorvastatin 10, 20, 40, or 80 mg (Pooled) | 0.0 |
Participants had AST and ALT levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of either AST or ALT that were 3 x ULN or greater were recorded. The AST UNLs for males and females were 43 U/L and 36 U/L, respectively. The ALT UNLs for males and females were 40 U/L and 33 U/L, respectively. (NCT00289900)
Timeframe: up to 12 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| MK-0524B 2g/20 mg and MK-0524B 2g/40mg (Pooled) | 0.4 |
| Atorvastatin 10, 20, 40, or 80 mg (Pooled) | 1.8 |
Participants had CK assessed throughout the 12 week treatment period. Participants who had any CK level that was >=10 x ULN were recorded. The UNLs for males and females were 207 U/L and 169 U/L, respectively. (NCT00289900)
Timeframe: up to 12 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled) | 0.1 |
| Atorvastatin 10, 20, 40, or 80 mg (Pooled) | 0.1 |
Participants had AST and ALT levels assessed throughout the 12 week treatment period. Participants who had an assessment of either AST or ALT that was 10 x ULN or greater were recorded. The AST UNLs for males and females were 43 U/L and 36 U/L, respectively. The ALT UNLs for males and females were 40 U/L and 33 U/L, respectively. (NCT00289900)
Timeframe: up to 12 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled) | 0.0 |
| Atorvastatin 10, 20, 40, or 80 mg (Pooled) | 0.1 |
Participants had AST and ALT levels assessed throughout the 12 week treatment period. Participants who had an assessment of either AST or ALT that was 5 x ULN or greater were recorded. The AST UNLs for males and females were 43 U/L and 36 U/L, respectively. The ALT UNLs for males and females were 40 U/L and 33 U/L, respectively. (NCT00289900)
Timeframe: up to 12 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| MK-0524B 2g/20 mg and MK-0524B 2g/40mg (Pooled) | 0.1 |
| Atorvastatin 10, 20, 40, or 80 mg (Pooled) | 0.9 |
Participants had blood glucose levels assessed throughout the 12 week treatment period. Participants who with newly diagnosed of diabetes were recorded. A participant was classified as having new onset diabetes if they experienced an adverse Event (AE) related to a diagnosis of diabetes (based on a pre-defined set of Medical Dictionary for Regulatory Activities [MedDRA] terms), or if they started taking an anti-diabetic medication during the course of the study. The MedDRA terms were as follows: diabetes mellitus, diabetes mellitus insulin-dependent, diabetes mellitus non-insulin dependent, insulin-requiring type II diabetes mellitus, insulin resistant diabetes, diabetes with hyperosmolarity, latent autoimmune diabetes in adults. (NCT00289900)
Timeframe: up to 12 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled) | 0.9 |
| Atorvastatin 10, 20, 40, or 80 mg (Pooled) | 0.2 |
Participants had blood glucose levels assessed throughout the 12 week treatment period. Participants who had the new diagnosis of impaired fasting blood glucose were recorded. A pre-defined set of MedDRA terms was used to identify participants whose glycemic status became 'impaired' during the course of treatment (from clinical adverse experience reports). The MedDRA terms were as follows: blood glucose increased, blood glucose abnormal, glucose tolerance decreased, glucose tolerance test abnormal, carbohydrate tolerance decreased, glucose tolerance impaired, hyperglycaemia, impaired fasting glucose, impaired insulin secretion, metabolic syndrome, insulin resistance, insulin resistance syndrome. (NCT00289900)
Timeframe: up to 12 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled) | 0.2 |
| Atorvastatin 10, 20, 40, or 80 mg (Pooled) | 0.1 |
(NCT00108485)
Timeframe: Baseline, 1 year
| Intervention | mg/dL (Number) |
|---|---|
| Extended Release Niacin | 42 |
| Placebo | 63 |
(NCT00203476)
Timeframe: 12 weeks
| Intervention | participants (Number) |
|---|---|
| Niacin | 0 |
| Colestipol | 0 |
| Ezetimibe | 0 |
Each participant had his LDL goal calculated based on the NCEP ATPIII guidelines. (NCT00203476)
Timeframe: 12 weeks
| Intervention | participants (Number) |
|---|---|
| Niacin | 6 |
| Colestipol | 6 |
| Ezetimibe | 9 |
(NCT00203476)
Timeframe: 12 weeks
| Intervention | participants (Number) |
|---|---|
| Niacin | 1 |
| Colestipol | 1 |
| Ezetimibe | 2 |
(NCT00203476)
Timeframe: baseline and 12 weeks
| Intervention | mg/dl (Mean) | |
|---|---|---|
| baseline | 12 weeks | |
| Colestipol | 39.22 | 37.56 |
| Ezetimibe | 32.90 | 34.70 |
| Niacin | 42.33 | 43.00 |
119 reviews available for niacin and Hyperlipemia
| Article | Year |
|---|---|
Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.
Topics: Atherosclerosis; Ezetimibe; Fibric Acids; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl- | 2021 |
Controversies on HDL: should it be a target biomarker in patients with lipid disorders?
Topics: Apolipoprotein A-I; Biomarkers; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Choles | 2014 |
Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications.
Topics: Animals; Azetidines; Bile Acids and Salts; Blood Glucose; Cholesterol Ester Transfer Proteins; Diabe | 2014 |
Revising the high-density lipoprotein targeting strategies - insights from human and preclinical studies.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemic Agen | 2014 |
Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?
Topics: Animals; Cardiovascular Diseases; Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin; Risk Factor | 2015 |
Pharmacological Effects of Niacin on Acute Hyperlipemia.
Topics: Adenylyl Cyclases; Cholesterol, HDL; Cholesterol, LDL; Cyclooxygenase 1; Cyclooxygenase 2; Humans; H | 2016 |
Pleiotropic effects of niacin: Current possibilities for its clinical use.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Atherosclerosis; Disease Progression | 2016 |
Lipid lowering treatment patterns and goal attainment in Nordic patients with hyperlipidemia.
Topics: Cholesterol; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Humans; Hydroxymethylglu | 2008 |
LDL reduction: how low should we go and is it safe?
Topics: Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Coron | 2008 |
A review of trials evaluating nonstatin lipid-lowering therapies.
Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe | 2009 |
Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug | 2008 |
Lipid metabolism and hyperlipidemia in dogs.
Topics: Animals; Diet, Reducing; Dog Diseases; Dogs; Fatty Acids, Omega-3; Hyperlipidemias; Hypertriglycerid | 2010 |
Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
Topics: Animals; Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Cholesterol, LDL; Drug Therapy, | 2009 |
Second line options for hyperlipidemia management after cardiac transplantation.
Topics: Azetidines; Bezafibrate; Diet; Exercise; Ezetimibe; Fish Oils; Heart Transplantation; Humans; Hydrox | 2013 |
Nicotinic acid as a lipid-modifying drug--a review.
Topics: Animals; Biomarkers; Chemistry, Pharmaceutical; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipid | 2013 |
Understanding niacin formulations.
Topics: Chemistry, Pharmaceutical; Clinical Trials as Topic; Humans; Hyperlipidemias; Hypolipidemic Agents; | 2002 |
Niacin-based therapy for dyslipidemia: past evidence and future advances.
Topics: Adult; Anticholesteremic Agents; Cholesterol, HDL; Drug Therapy, Combination; Female; Humans; Hyperl | 2002 |
Treatment of dyslipidaemia in high-risk patients: too little, too late.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combin | 2002 |
Management of hypercholesterolaemia in the patient with diabetes.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, T | 2002 |
Current drug treatments for lipid management.
Topics: Bile Acids and Salts; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Clofibric Acid; | 2002 |
Combination therapy for combined dyslipidemia.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fatty | 2002 |
Niacin extended-release/lovastatin: combination therapy for lipid disorders.
Topics: Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Humans; Hyperlipidemias; H | 2002 |
Management of dyslipidemia in the high-risk patient.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Delayed-Action Preparations; Drug Therapy, Combination; | 2002 |
Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Delayed-Action Preparations; Drug Comb | 2003 |
Therapy to reduce risk of coronary heart disease.
Topics: Anion Exchange Resins; Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Humans; | 2003 |
What future for combination therapies?
Topics: Bile Acids and Salts; Clofibric Acid; Drug Therapy, Combination; Fish Oils; Forecasting; Humans; Hyp | 2003 |
Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2003 |
Toxicity of antilipidemic agents: facts and fictions.
Topics: Chemical and Drug Induced Liver Injury; Drug Interactions; Drug Therapy, Combination; Humans; Hydrox | 2003 |
Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events.
Topics: Acute Disease; Algorithms; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Diab | 2003 |
Niacin as a component of combination therapy for dyslipidemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Delayed-Action Prepa | 2003 |
Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia.
Topics: Abdomen; Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhi | 2003 |
[MECHANISM OF ACTION OF LIPEMIA-CLEARING PREPARATIONS].
Topics: Dextrans; Edetic Acid; Heparin; Hyperlipidemias; Lipoprotein Lipase; Neomycin; Niacin; Nicotinic Aci | 1963 |
What's new in lipid management?
Topics: Bile Acids and Salts; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hydroxymethylglut | 2003 |
Antiatherothrombotic effects of nicotinic acid.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Fibrinolytic Agents; Humans; Hydroxymethylglut | 2003 |
The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin.
Topics: Adult; Aged; Cholesterol; Coronary Disease; Cost-Benefit Analysis; Female; Humans; Hyperlipidemias; | 2004 |
The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels.
Topics: Fenofibrate; Homocysteine; Humans; Hyperhomocysteinemia; Hyperlipidemias; Hypolipidemic Agents; Niac | 2004 |
Dyslipidemia treatment: current considerations and unmet needs.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clinical Trials as Topic; Drug Therapy, Combination; | 2003 |
New perspectives on the use of niacin in the treatment of lipid disorders.
Topics: Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Dose-Response Relationship, Drug; D | 2004 |
Combination therapy for the treatment of dyslipidemia.
Topics: Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; | 2004 |
Extended-release niacin for modifying the lipoprotein profile.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Delayed-Action Preparations; Humans; H | 2004 |
A meta-analysis of randomized controlled studies on the effects of extended-release niacin in women.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Double-Blind Method; F | 2004 |
Combination therapy in the management of complex dyslipidemias.
Topics: Algorithms; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Drug Therapy, Combination | 2004 |
Treating low HDL--from bench to bedside.
Topics: Animals; Cholesterol; Coronary Artery Disease; Coronary Disease; Endothelium, Vascular; Humans; Hype | 2004 |
Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug.
Topics: Arteriosclerosis; Delayed-Action Preparations; Double-Blind Method; Fatty Acids, Nonesterified; Fema | 2004 |
Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Fenofibrate; Gemfibrozil; Human | 2004 |
The emerging role of lipoproteins in atherogenesis: beyond LDL cholesterol.
Topics: Animals; Arteriosclerosis; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; | 2004 |
Addressing cardiovascular risk beyond low-density lipoprotein cholesterol: the high-density lipoprotein cholesterol story.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Humans; Hydr | 2004 |
The effects of niacin on lipoprotein subclass distribution.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Humans; Hyperlipidemias; Niacin | 2004 |
[Low HDL-cholesterol, high triglycerides--well known but often ignored].
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Clofibric A | 2004 |
Clinical update on the use of niacin for the treatment of dyslipidemia.
Topics: Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin; Practice Guidelines as Topic; Safety; Treatme | 2004 |
Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein.
Topics: Cholesterol, LDL; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipid | 2005 |
Rationale for combination therapy with statin drugs in the treatment of dyslipidemia.
Topics: Anion Exchange Resins; Antihypertensive Agents; Azetidines; Benzenesulfonates; Clofibric Acid; Drug | 2005 |
[Dyslipidemia management in patients with impaired glucose tolerance].
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholesterol, HDL; Clofibric Acid; Eicosapen | 2005 |
Update on risk factors for atherosclerosis: the role of inflammation and apolipoprotein E.
Topics: Apolipoproteins E; Arteriosclerosis; Cholestyramine Resin; Diet, Fat-Restricted; Exercise; Genotype; | 2005 |
[Niacin--an additive therapeutic approach for optimizing lipid profile].
Topics: Cholesterol; Cholesterol, HDL; Controlled Clinical Trials as Topic; Coronary Disease; Drug Therapy, | 2005 |
Commentary: A new approach to atherogenic dyslipidemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Humans; Hyperlipidemias; Hypolipidemic | 2005 |
Cholesterol lowering in diabetes. New evidence supports aggressive LDL-C targets.
Topics: Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Drug Therapy, Combination; Humans; Hyperlipid | 2005 |
Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Europe; Humans; Hyperlipidemias; Hypolipidemic A | 2005 |
Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review.
Topics: Adipose Tissue; Arteriosclerosis; Coronary Disease; Fatty Acids, Nonesterified; Fibrinolysis; Flushi | 2005 |
Management of dyslipidemia in patients with complicated metabolic syndrome.
Topics: Clofibric Acid; Fatty Liver; HIV-Associated Lipodystrophy Syndrome; Humans; Hydroxymethylglutaryl-Co | 2005 |
Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention.
Topics: Arteries; Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Drug Evaluation; Humans; Hyperlipidem | 2005 |
Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events.
Topics: Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Cholestyramine Resin; Clofibric Acid; Drug Th | 2006 |
[Nicotinic acid: an unjustly neglected remedy].
Topics: Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin | 2006 |
[Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric | 2007 |
[Niacin in therapy].
Topics: Adipocytes; Adiponectin; Animals; Cholesterol, HDL; Delayed-Action Preparations; Flushing; Humans; H | 2007 |
Present-day uses of niacin: effects on lipid and non-lipid parameters.
Topics: Animals; Cholesterol, HDL; Cholesterol, LDL; Humans; Hyperlipidemias; Lipids; Metabolic Syndrome; Ni | 2007 |
Nicotinic acid: pharmacological effects and mechanisms of action.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hyperlipidemias | 2008 |
Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?
Topics: Aspirin; Drug Combinations; Dyslipidemias; Health Services Needs and Demand; Humans; Hydroxymethylgl | 2007 |
FPIN's clinical inquiries. Best alternatives to statins for treating hyperlipidemia.
Topics: Anion Exchange Resins; Azetidines; Clofibric Acid; Evidence-Based Medicine; Ezetimibe; Fatty Acids, | 2007 |
Nicotinic acid in the treatment of hyperlipidaemia.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin | 2007 |
Management of hyperlipidemia with statins in the older patient.
Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA | 2006 |
Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol | 2008 |
Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Aci | 2008 |
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl | 1984 |
Therapy of hyperlipidemic states.
Topics: Cholesterol, Dietary; Cholestyramine Resin; Clofibrate; Colestipol; Dietary Fats; Drug Therapy, Comb | 1982 |
Niacin for lipid disorders. Indications, effectiveness, and safety.
Topics: Contraindications; Drug Eruptions; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Liver; Mal | 1995 |
Hyperlipidemia: perspectives in diagnosis and treatment.
Topics: Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Coronary Disease; Diet, Fat-Re | 1995 |
Niacin-induced myopathy.
Topics: Aged; Aged, 80 and over; Female; Humans; Hyperlipidemias; Male; Muscular Diseases; Niacin | 1994 |
Niacin: a therapeutic dilemma. "One man's drink is another's poison".
Topics: Delayed-Action Preparations; Humans; Hyperlipidemias; Niacin | 1994 |
Dyslipidemia and coronary artery disease.
Topics: Arteriosclerosis; Cholesterol; Coronary Disease; Drug Therapy, Combination; Exercise; Gemfibrozil; H | 1994 |
Number-needed-to-treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy.
Topics: Coronary Angiography; Coronary Artery Disease; Disease Progression; Female; Humans; Hydroxymethylglu | 1996 |
Trials of the effects of drugs and hormones on lipids and lipoproteins.
Topics: Clinical Trials as Topic; Estrogen Replacement Therapy; Female; Hormones; Human Growth Hormone; Huma | 1995 |
New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug.
Topics: Apolipoprotein B-100; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Follow-Up | 1996 |
Lipid management: current diet and drug treatment options.
Topics: Diet; Gemfibrozil; Humans; Hyperlipidemias; Niacin; Patient Education as Topic | 1996 |
Choosing the right lipid-regulating agent. A guide to selection.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Fenofibrat | 1996 |
[The role of nicotinic acid in the treatment of atherosclerosis and atherogenic dyslipidemia].
Topics: Arteriosclerosis; Humans; Hyperlipidemias; Lipids; Niacin; Treatment Outcome | 1996 |
Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Disease; | 1998 |
Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice?
Topics: Animals; Disease Models, Animal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipide | 1998 |
Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiologic rationale for nighttime dosing.
Topics: Circadian Rhythm; Delayed-Action Preparations; Drug Administration Schedule; Humans; Hyperlipidemias | 1998 |
Treatment of hyperlipidemia with combined niacin-statin regimens.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Delayed-Action Preparations; Drug Therapy, Combi | 1998 |
Drug treatment of lipid disorders.
Topics: Anion Exchange Resins; Cardiovascular Diseases; Clofibrate; Female; Humans; Hydroxymethylglutaryl-Co | 1999 |
Pharmacology department: pharmacologic approaches to abnormal blood lipids.
Topics: Anion Exchange Resins; Antioxidants; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Red | 2000 |
Combination drug therapy for combined hyperlipidemia.
Topics: Arteriosclerosis; Drug Therapy, Combination; Fish Oils; Humans; Hyperlipidemias; Hypolipidemic Agent | 1999 |
Novel lipid-regulating drugs.
Topics: Animals; Anticholesteremic Agents; Bile Acids and Salts; Carrier Proteins; Cholesterol Ester Transfe | 2000 |
Combination drug therapy for dyslipidemia.
Topics: Anion Exchange Resins; Cholesterol, LDL; Drug Therapy, Combination; Fish Oils; Humans; Hydroxymethyl | 1999 |
Use of niacin in the prevention and management of hyperlipidemia.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Monitoring; Humans; Hyperlipidemias; Liver Fun | 2001 |
[Drug combination therapies for patients with hyperlipidemia and its significance].
Topics: Anion Exchange Resins; Bezafibrate; Cholesterol, LDL; Cost-Benefit Analysis; Drug Therapy, Combinati | 2001 |
[Nicotinic acid and the derivative].
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Hum | 2001 |
Dyslipidemia, gender, and the role of high-density lipoprotein cholesterol: implications for therapy.
Topics: Adult; Aging; Cholesterol, HDL; Coronary Disease; Female; Humans; Hyperlipidemias; Male; Menopause; | 2000 |
Divergent approaches to the treatment of dyslipidemia with low levels of high-density lipoprotein cholesterol.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Drug Combinations; Ethanol; Gemfibrozil; Humans; Hydroxy | 2000 |
Clinical treatment of dyslipidemia: practice patterns and missed opportunities.
Topics: Age Distribution; Aged; Coronary Disease; Female; Humans; Hyperlipidemias; Male; Medical Records Sys | 2000 |
Treating mixed dyslipidemias: why and how.
Topics: Cholesterol, HDL; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlip | 2001 |
Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century.
Topics: Coronary Disease; Drug Interactions; Drug Therapy, Combination; Humans; Hypercholesterolemia; Hyperl | 2001 |
Pathophysiology and treatment of the dyslipidemia of insulin resistance.
Topics: Cardiovascular Diseases; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; | 2001 |
Managing dyslipidemia in the high-risk patient.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Tria | 2002 |
Should pediatric patients with hyperlipidemia receive drug therapy?
Topics: Anticholesteremic Agents; Child; Cholestyramine Resin; Coronary Disease; Fatty Acids, Omega-3; Human | 2002 |
Drug therapy of hyperlipidemia.
Topics: Anticholesteremic Agents; Butyrates; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; | 1992 |
Cholesterol-lowering drugs as cardioprotective agents.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA | 1992 |
Effects of various lipid-lowering treatments in diabetics.
Topics: Clofibrate; Diabetes Complications; Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase I | 1990 |
Use of niacin as a drug.
Topics: Animals; Humans; Hyperlipidemias; Lipoproteins, VLDL; Liver; Niacin; Niacinamide; Structure-Activity | 1991 |
Management of hyperlipidemia of kidney disease.
Topics: Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolem | 1990 |
Drug therapy in dyslipidemia.
Topics: Anticholesteremic Agents; Bile Acids and Salts; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA | 1990 |
Nicotinic acid: a review of its clinical use in the treatment of lipid disorders.
Topics: Humans; Hyperlipidemias; Niacin | 1988 |
When to treat hyperlipidemia.
Topics: Animals; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; H | 1988 |
Reducing cardiac deaths with hypolipidemic drugs.
Topics: Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Feeding Behavior; Gemfi | 1987 |
Contemporary recommendations for evaluating and treating hyperlipidemia.
Topics: Clofibrate; Dextrothyroxine; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lip | 1986 |
The diagnosis and management of hyperlipidemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibr | 1986 |
Pharmacological modification of lipoprotein metabolism.
Topics: Animals; Bile Acids and Salts; Cholestyramine Resin; Clofibrate; Colestipol; Humans; Hydroxymethylgl | 1987 |
Antihyperlipidemic properties of beta-pyridylcarbinol. A review of preclinical studies.
Topics: Adipose Tissue; Adrenal Cortex; Animals; Blood Glucose; Cholesterol; Cholesterol, Dietary; Coronary | 1985 |
46 trials available for niacin and Hyperlipemia
| Article | Year |
|---|---|
Plasma Lipidome Analysis by Liquid Chromatography-High Resolution Mass Spectrometry and Ion Mobility of Hypertriglyceridemic Patients on Extended-Release Nicotinic Acid: a Pilot Study.
Topics: Adult; Cholesterol, HDL; Chromatography, Liquid; Cross-Over Studies; Delayed-Action Preparations; Do | 2017 |
Impaired lipoprotein processing in HIV patients on antiretroviral therapy: aberrant high-density lipoprotein lipids, stability, and function.
Topics: Anti-Retroviral Agents; Biomarkers; Cell Line, Tumor; Cholesterol Esters; Combined Modality Therapy; | 2013 |
Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.
Topics: Aged; Azetidines; Biomarkers; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; D | 2013 |
Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Apolipoprotein B-100; Blood Glucose; Cholesterol, HDL; Cholesterol, | 2016 |
Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoprotein B-100; Apolipoprotein B-48; Cho | 2008 |
Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
Topics: Adolescent; Adult; Aged; Azetidines; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, | 2010 |
Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Delayed-Action Preparations; Diabetes Mellit | 2010 |
Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Delayed-Act | 2010 |
Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combinati | 2013 |
Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial.
Topics: Adolescent; Adult; Age of Onset; Aged; Azetidines; Delayed-Action Preparations; Diabetes Complicatio | 2012 |
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol, HDL; Chole | 2002 |
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Delayed-Action Preparations; Dose-R | 2003 |
A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin.
Topics: Analysis of Variance; Chi-Square Distribution; Delayed-Action Preparations; Dose-Response Relationsh | 2003 |
Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels.
Topics: Adolescent; Adult; Cholesterol, HDL; Creatine Kinase; Delayed-Action Preparations; Dose-Response Rel | 2003 |
[Comparative efficiency of prolonged diet and drug therapies for hyperlipidemias in patients with ischemic heart disease].
Topics: Aged; Bezafibrate; Cholesterol, LDL; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Mi | 2004 |
Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study.
Topics: Administration, Oral; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administra | 2004 |
Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Cholesterol; Delayed-Action Preparations; Glucose Tolerance T | 2004 |
Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia.
Topics: Adult; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations | 2004 |
Effects of combined dietary supplementation on oxidative and inflammatory status in dyslipidemic subjects.
Topics: Adult; Aged; Antioxidants; Atherosclerosis; Cytokines; Dietary Supplements; Drug Therapy, Combinatio | 2006 |
Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia.
Topics: Adult; Antiretroviral Therapy, Highly Active; Combined Modality Therapy; Diet, Fat-Restricted; Exerc | 2006 |
[Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coron | 2006 |
Treatment of hyperlipidaemia and progression of atherosclerosis.
Topics: Adult; Arteriosclerosis; Colestipol; Double-Blind Method; Female; Humans; Hyperlipidemias; Middle Ag | 1983 |
The prevalence of side effects with regular and sustained-release nicotinic acid.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Delayed-Action Preparations; Female; Human | 1995 |
Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients.
Topics: Adult; Aged; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug | 1994 |
Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial.
Topics: Adult; Anticholesteremic Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cro | 1995 |
Nicotinic acid decreases serum thyroid hormone levels while maintaining a euthyroid state.
Topics: Adult; Female; Humans; Hyperlipidemias; Liver; Liver Function Tests; Male; Middle Aged; Niacin; Thyr | 1995 |
The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hyperlipidemias; Hypol | 1993 |
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, | 1995 |
Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over S | 1997 |
Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease.
Topics: Cholesterol, LDL; Colestipol; Cross-Over Studies; Delayed-Action Preparations; Drug Therapy, Combina | 1997 |
Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl.
Topics: Aged; Brachial Artery; Cholestyramine Resin; Coronary Disease; Double-Blind Method; Drug Therapy, Co | 1997 |
A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; H | 1998 |
Efficacy and safety of one-year treatment with slow-release nicotinic acid. Monitoring of drug concentration in serum.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Biomarkers; Delayed- | 1998 |
Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
Topics: Double-Blind Method; Drug Administration Schedule; Female; Humans; Hyperlipidemias; Male; Middle Age | 1998 |
Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia.
Topics: Adult; Aged; Apolipoproteins B; Cholesterol, LDL; Double-Blind Method; Female; Humans; Hyperlipidemi | 2000 |
Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment.
Topics: Analysis of Variance; Cholesterol, HDL; Colestipol; Coronary Angiography; Coronary Disease; Drug The | 2001 |
Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects.
Topics: Analysis of Variance; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clofibric Acid; Double- | 2001 |
Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Female; Heptanoic Acids; Humans; Hyperlipi | 2001 |
Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy.
Topics: Adult; Aged; Analysis of Variance; Coronary Disease; Drug Therapy, Combination; Female; Humans; Hype | 2002 |
Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.
Topics: Adult; Aged; Aged, 80 and over; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Delayed-Acti | 2002 |
Cholesterol-lowering drugs as cardioprotective agents.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA | 1992 |
A clinical trial of oat bran and niacin in the treatment of hyperlipidemia.
Topics: Adult; Aged; Delayed-Action Preparations; Drug Therapy, Combination; Edible Grain; Female; Humans; H | 1992 |
A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia.
Topics: Adult; Aged; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niaci | 1992 |
The effect of aspirin on niacin-induced cutaneous reactions.
Topics: Adult; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Flushing; Humans; Hyperlipid | 1992 |
[Angiographic regression of coronary atheromatosis].
Topics: Angiography; Anticholesteremic Agents; Coronary Angiography; Coronary Artery Disease; Drug Therapy, | 1991 |
Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin.
Topics: Adult; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins A; Cholesterol, HDL; Cholesterol, LD | 1985 |
135 other studies available for niacin and Hyperlipemia
| Article | Year |
|---|---|
Molecular identification of high and low affinity receptors for nicotinic acid.
Topics: Amino Acid Sequence; Animals; Cell Membrane; CHO Cells; Cricetinae; Databases as Topic; DNA, Complem | 2003 |
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; | 2017 |
Safety assessment of niacin in the US Food and Drug Administration's mini-sentinel system.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Cholesterol, HDL; Delayed-A | 2018 |
Hydroxytyrosol nicotinate, a new multifunctional hypolipidemic and hypoglycemic agent.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hy | 2018 |
Evolution of Ellipsoid Zone Abnormalities on Optical Coherence Tomography Associated With Niacin Maculopathy.
Topics: Fluorescein Angiography; Humans; Hyperlipidemias; Macular Edema; Male; Middle Aged; Niacin; Tomograp | 2019 |
Hyperlipidaemia and cardiovascular disease: the quantity does not turn into quality!
Topics: Amides; Cardiovascular Diseases; Drug Therapy, Combination; Esters; Humans; Hyperlipidemias; Niacin; | 2013 |
[Relationship of ox-LDL/LOX-1 and vascular endothelial dysfunction of diet-induced obese immature rats and nicotinic acid's intervention outcomes].
Topics: Animals; Endothelium, Vascular; Hyperlipidemias; Intercellular Adhesion Molecule-1; Lipoproteins, LD | 2013 |
Drugs for lipids.
Topics: Animals; Azetidines; Cholesterol; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Fish Oils | 2014 |
Prolonged niacin treatment leads to increased adipose tissue PUFA synthesis and anti-inflammatory lipid and oxylipin plasma profile.
Topics: Algorithms; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apolipoprotein E3; Arachidonic Acid; B | 2014 |
Beyond statins: assessing the alternatives. Some people can't tolerate statins, and others need additional medications to achieve healthy cholesterol levels.
Topics: Anticholesteremic Agents; Azetidines; Bezafibrate; Cholesterol; Dietary Supplements; Exercise; Ezeti | 2014 |
The use of a hydrogel matrix for controlled delivery of niacin to the gastrointestinal tract for treatment of hyperlipidemia.
Topics: Cross-Linking Reagents; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Gastroint | 2015 |
Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease: A Retrospective Cohort Study in the Medicare Population 2007 to 2011.
Topics: Adult; Anticholesteremic Agents; Coronary Disease; Drug Utilization; Ezetimibe; Humans; Hyperlipidem | 2015 |
Potentially Reversible Effect of Niacin Therapy on Edema From Retinal Vein Occlusion.
Topics: Administration, Oral; Humans; Hyperlipidemias; Hypertension; Macular Edema; Male; Middle Aged; Niaci | 2016 |
Combined effects of niacin and chromium treatment on vascular endothelial dysfunction in hyperlipidemic rats.
Topics: Animals; Chromium; Down-Regulation; Drug Therapy, Combination; Endothelium, Vascular; Hyperlipidemia | 2009 |
Should we treat all primary prevention patients with statins?
Topics: Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Cholesterol; Drug Therapy, Combination; E | 2009 |
Lipid disorders.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary D | 2009 |
LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fenofi | 2010 |
Hyperlipidaemia and cardiovascular disease: low HDL-cholesterol as a therapeutic target in statin-treated patients: a role for nicotinic acid (niacin)?
Topics: Cardiovascular Diseases; Cholesterol, HDL; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Redu | 2010 |
Therapy and clinical trials: HDL-cholesterol and niacin therapy--past, present, and future.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Humans; Hydroxymethylglutaryl-CoA Redu | 2010 |
What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
Topics: Biomarkers; Cardiovascular Diseases; Carotid Artery Diseases; Cholesterol, HDL; Cholesterol, LDL; Dr | 2010 |
Niacin, fenofibrates increase benefits for statin users. These HDL- raising, triglyceride-lowering drugs beat out the use of additional LDL-lowering drugs.
Topics: Carotid Artery Diseases; Cholesterol, HDL; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidem | 2010 |
Analgesic benefit of niacin for shrapnel wound pain in war veteran.
Topics: Aged, 80 and over; Analgesia; Blast Injuries; Cicatrix, Hypertrophic; Humans; Hyperlipidemias; Hypol | 2010 |
Combined effects of niacin and chromium treatment on heart of hyperlipidemic rats.
Topics: Animals; Aryldialkylphosphatase; Chromium; Diet, Atherogenic; Female; gamma-Glutamyltransferase; Glu | 2011 |
Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile.
Topics: Chromatography, High Pressure Liquid; Esters; Gemfibrozil; Half-Life; Humans; Hydrogen-Ion Concentra | 2011 |
Combining niacin with statins: does it help heart health?
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Drug Interactions; Drug Therapy, Combi | 2011 |
I am among the minority of people who have experienced serious side effects from using a statin. Along with healthy lifestyle choices, are there any other non-statin medications that can help?
Topics: Anticholesteremic Agents; Health Behavior; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; H | 2010 |
Niacin seems OK for people with diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Niacin | 2002 |
The rationale for combination therapy.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combin | 2002 |
Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Humans; Hyd | 2002 |
Existing and investigational combination drug therapy for high-density lipoprotein cholesterol.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Coronary Disease; Drug Therapy, Combination; Estrogens; | 2002 |
Use of combination therapy for dyslipidemia: a lipid clinic approach.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; | 2002 |
Combination therapy for dyslipidemia: safety and regulatory considerations.
Topics: Algorithms; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, | 2002 |
Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Coronary Disease; Drug | 2002 |
The use of niacin in diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypolipidemi | 2003 |
Three new drugs for hyperlipidemia.
Topics: Azetidines; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Ezetim | 2003 |
Niacin for dyslipidemia: considerations in product selection.
Topics: Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin; Patient Compliance; Practice Guidelines as To | 2003 |
Three new drugs for hyperlipidemia.
Topics: Azetidines; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; | 2003 |
Effectiveness of aggressive management of dyslipidemia in a collaborative-care practice model.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Coop | 2003 |
Niacin in the treatment of dyslipidemia: insight from Adult Treatment Panel III. Introduction.
Topics: Adult; Aged; Cardiovascular Diseases; Female; Humans; Hyperlipidemias; Male; Middle Aged; Niacin | 2003 |
Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety.
Topics: Administration, Oral; Chemistry, Pharmaceutical; Clinical Trials as Topic; Delayed-Action Preparatio | 2003 |
Advances in the understanding and management of dyslipidemia: using niacin-based therapies.
Topics: Chemistry, Pharmaceutical; Cholesterol, HDL; Coronary Artery Disease; Delayed-Action Preparations; D | 2003 |
Niacin and the National Cholesterol Education Program Adult Treatment Panel III Guidelines: case studies.
Topics: Aspirin; Atenolol; Blood Chemical Analysis; Coronary Disease; Female; Humans; Hyperlipidemias; Hyper | 2003 |
Oral nicotinic acid for hyperlipemia with emphasis on side effects.
Topics: Humans; Hyperlipidemias; Lipids; Niacin; Nicotinic Acids | 1958 |
Some observations on the relationships between atherosclerosis, hyperlipemia, and D-thyroxine.
Topics: Arteriosclerosis; Atherosclerosis; Cholesterol; Dextrothyroxine; Estrogens; Humans; Hyperlipidemias; | 1962 |
Nicotinic acid levels as an index of aluminum nicotinate activity in the treatment of hyperlipemia.
Topics: Aluminum; Hyperlipidemias; Niacin; Nicotinic Acids | 1962 |
Aluminum nicotinate in the treatment of hypercholesteremia, hyperlipemia, and other elevated lipid levels.
Topics: Aluminum; Aluminum Compounds; Hypercholesterolemia; Hyperlipidemias; Lipids; Niacin; Nicotinic Acids | 1962 |
Treatment of "idiopathic" hyperlipemia.
Topics: Hyperlipidemias; Lipids; Niacin; Nicotinic Acids; Tolbutamide | 1962 |
[Effect of Lipokapsul on the serum lipids in arteriosclerosis (with reference to different diet forms)].
Topics: Arteriosclerosis; Coronary Disease; Diet; Diet Therapy; Fatty Acids; Fatty Acids, Essential; Humans; | 1962 |
EFFECT OF NICOTINIC ACID ON ABNORMAL SERUM LIPIDS.
Topics: Child; Cholesterol; Geriatrics; Hypercholesterolemia; Hyperlipidemias; Lipid Metabolism; Lipids; Lip | 1964 |
[FAMILIAL XANTHOMATOUS HYPERCHOLESTEREMIA].
Topics: Adrenocorticotropic Hormone; Cortisone; Diagnosis, Differential; Diet; Diet Therapy; Dietary Fats; E | 1963 |
[STUDIES ON THE TREATMENT OF ENDOGENOUS HYPERLIPOPROTEINEMIA WITH BETA-PYRIDYL-CARBINOL].
Topics: Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemias; Lipoproteins; Methanol; Niacin | 1963 |
[THE SIGNIFICANCE OF INSUFFICIENT CLEARANCE IN ATHEROGENESIS].
Topics: Arteriosclerosis; Atherosclerosis; Dietary Fats; Glycerides; Heparin; Heparinoids; Hypercholesterole | 1963 |
[PROLONGED TREATMENT WITH LARGE DOSES OF NICOTINIC ACID IN CORONARY ARTERIOSCLEROSIS].
Topics: Coronary Artery Disease; Coronary Disease; Humans; Hyperlipidemias; Niacin; Nicotinic Acids | 1964 |
[STUDIES ON THE INFLUENCING OF FAT CLEARANCE IN VIVO].
Topics: Adenosine Triphosphate; Arteriosclerosis; Dietary Fats; Heparin; Hyperlipidemias; Hypertension; Iodi | 1964 |
[ON CHOLESTEROL MOBILIZATION IN THE TREATMENT OF XANTHOMA AND ATHEROSCLEROSIS].
Topics: Arteriosclerosis; Atherosclerosis; Cholesterol; Drug Therapy; Heparin; Humans; Hypercholesterolemia; | 1963 |
[COMPLAMINE TREATMENT OF PATIENTS WITH INCREASED SERUM CHOLESTEROL VALUES].
Topics: Cholesterol; Coronary Disease; Humans; Hypercholesterolemia; Hyperlipidemias; Niacin; Nicotinic Acid | 1964 |
[BLOOD LIPIDS IN ATHEROSCLEROSIS AND THE ACTION OF SOME AGENTS MODIFYING LIPEMIA].
Topics: Androsterone; Anticholesteremic Agents; Arteriosclerosis; Atherosclerosis; Butyrates; Cholesterol; D | 1964 |
[RESEARCH ON THE INFLUENCE OF NICOTINIC ACID ON SERUM LIPID FRACTIONS].
Topics: Drug Therapy; Humans; Hyperlipidemias; Lipids; Niacin; Nicotinic Acids; Research | 1964 |
[NEW POSSIBILITIES IN THE DIAGNOSIS AND MEASURES FOR DRUG CONTROL OF DEGENERATIVE VASCULAR DISEASES].
Topics: Anticholesteremic Agents; Arteriosclerosis; Blood Chemical Analysis; Cardiovascular Diseases; Corona | 1964 |
[STUDIES ON THE CONTROLLABILITY OF FAT-CLEARANCE INSUFFICIENCY].
Topics: Humans; Hyperlipidemias; Lipid Metabolism; Niacin; Nicotinic Acids; Vascular Diseases | 1964 |
Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Combinations; Female; Heptanoic Acids; | 2003 |
Effect of baseline levels on response of high-density lipoprotein cholesterol to hypolipidemic treatment.
Topics: Cholesterol, HDL; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Linear Models; Male; Middle | 2003 |
[New drug against lipid disorders. HDL level rises 30%].
Topics: Cholesterol, HDL; Coronary Disease; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Life Styl | 2003 |
Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia.
Topics: Chromatography, High Pressure Liquid; Dosage Forms; Fees, Pharmaceutical; Humans; Hyperlipidemias; N | 2003 |
[HDL cholesterol as protective factor. Deficiency threatens the diabetic heart].
Topics: Cholesterol, HDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypo | 2003 |
Purported benefits of inositol niacinate.
Topics: Administration, Oral; Anticholesteremic Agents; Humans; Hyperlipidemias; Inositol; Lipoproteins, VLD | 2004 |
Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Cholesterol, LDL; Clinical Trials as Topic; Creat | 2004 |
Beneficial effects of combined treatment with niacin and chromium on the liver of hyperlipemic rats.
Topics: Animals; Cholesterol; Chromium; Dietary Fats; Female; Hyperlipidemias; Hypolipidemic Agents; Lipids; | 2004 |
Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Topics: Aged; Ambulatory Care; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Comorbidity; Cross-Sectional Stu | 2005 |
Effects of a combination of niacin and chromium(III)-chloride on the skin and lungs of hyperlipemic rats.
Topics: Animals; Chlorides; Chromium Compounds; Diet; Female; Glutathione; Hyperlipidemias; Lipid Peroxidati | 2005 |
Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia.
Topics: Adult; Aged; Blood Glucose; Crystallization; Delayed-Action Preparations; Diabetes Mellitus; Fatty A | 2005 |
Cloricromene effect on the enzyme activities of the tryptophan-nicotinic acid pathway in diabetic/hyperlipidemic rabbits.
Topics: Animals; Cholesterol, Dietary; Chromonar; Diabetes Mellitus, Experimental; Free Radical Scavengers; | 2006 |
[Innovative therapies in metabolic diseases: ezetimibe (Ezétrol), nicotinic acid (Niaspan), acids omega-3 (Omacor), rimonabant (Acomplia)].
Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Fatty Acids, Omega-3; Humans; Hyperlipidemias; Hypo | 2005 |
The effect of combined treatment with niacin and chromium (III) chloride on the different tissues of hyperlipemic rats.
Topics: Animals; Catalase; Chlorides; Cholesterol; Chromium Compounds; Dietary Fats; Disease Models, Animal; | 2006 |
Adipokines and treatment with niacin.
Topics: Adiponectin; Adult; Aged; Cholesterol; Cholesterol, HDL; Cytokines; Delayed-Action Preparations; Fem | 2006 |
The effects of combined treatment with niacin and chromium on the renal tissues of hyperlipidemic rats.
Topics: Animals; Chromium; Creatinine; Dietary Fats; Drug Therapy, Combination; Female; Glutathione; Hyperli | 2007 |
Ameliorating effect of coenzyme Q10, riboflavin and niacin in tamoxifen-treated postmenopausal breast cancer patients with special reference to lipids and lipoproteins.
Topics: Adult; Aged; Breast Neoplasms; Cholesterol, LDL; Cholesterol, VLDL; Coenzymes; Drug Therapy, Combina | 2007 |
Cholesterol efflux and the effect of combined treatment with niacin and chromium on aorta of hyperlipidemic rat.
Topics: Adipose Tissue; Animals; Aorta; Cholesterol; Chromium; Drug Synergism; Endothelial Cells; Female; Gl | 2008 |
[Effect of niacin on HDL-induced cholesterol efflux and LXRalpha expression in adipocytes of hypercholesterolemic rabbits].
Topics: Adipocytes; Animals; Cholesterol; Disease Models, Animal; DNA-Binding Proteins; Hypercholesterolemia | 2007 |
Assessment of hypolipidaemic activity of three thiazolidin-4-ones in mice given high-fat diet and fructose.
Topics: Administration, Oral; Animals; Blood Glucose; Cholesterol; Diet; Dietary Fats; Disease Models, Anima | 2008 |
[Safety and effectiveness of nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphosphatemia].
Topics: Chronic Disease; Female; Humans; Hyperlipidemias; Hyperphosphatemia; Hypolipidemic Agents; Kidney Di | 2008 |
[Use of prolonged-release nicotinic acid in patients treated with statins as a secondary prevention and a persistently low HDL-cholesterol level in France].
Topics: Cholesterol, HDL; Delayed-Action Preparations; Female; France; Humans; Hydroxymethylglutaryl-CoA Red | 2008 |
Abnormalities of lipid metabolism and methods of their correction in patients with glomerulonephritis.
Topics: Adolescent; Adult; Arteriosclerosis; Clofibrate; Dipyridamole; Female; Glomerulonephritis; Humans; H | 1984 |
Gemfibrozil in combination with other drugs for severe hyperlipidemia. Preliminary study comprising four cases.
Topics: Adult; Cholesterol; Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Female; Gemfibrozil | 1983 |
Pharmacologic therapy for the hyperlipidemic patient.
Topics: Bile Acids and Salts; Clofibrate; Dextrothyroxine; Humans; Hyperlipidemias; Hypolipidemic Agents; Ni | 1983 |
Severe hypertriglyceridaemia responding to insulin and nicotinic acid therapy.
Topics: Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Humans; Hypercholesterolemia; | 1981 |
The spontaneously hyperlipidemic old rat as a model for evaluation of hypolipoproteinemic drugs. Effects of nicotinic acid, clofibrate and ethyl 2-(4-dibenzofuranyloxy)-2-methylpropionate on plasma lipoproteins.
Topics: Aging; Animals; Cholesterol; Clofibrate; Drug Evaluation, Preclinical; Hyperlipidemias; Lipoproteins | 1982 |
Criteria for use of hypolipidemic agents in adults.
Topics: Adult; Anticholesteremic Agents; Cholestyramine Resin; Colestipol; Female; Gemfibrozil; Humans; Hydr | 1994 |
Adverse ocular effects associated with niacin therapy.
Topics: Adult; Aged; Aged, 80 and over; Edema; Eye Diseases; Eyelid Diseases; Female; Humans; Hyperlipidemia | 1995 |
Why aren't we using more niacin?
Topics: Humans; Hyperlipidemias; Niacin | 1994 |
Effects of nicotinic acid treatment on glyceride formation and lipolysis in adipose tissue of hyperlipidemic patients.
Topics: Adipose Tissue; Adult; Aged; Fatty Acids; Female; Follow-Up Studies; Glucose; Glycerides; Humans; Hy | 1993 |
Effect of a combination of gemfibrozil and niacin on lipid levels.
Topics: Diet Therapy; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic | 1996 |
Relative effectiveness of niacin and lovastatin for treatment of dyslipidemias in a health maintenance organization.
Topics: Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Female; Follow-Up Studies; Health Maintenance Or | 1997 |
[The effect of long-term Enduracin monotherapy on the clinical and biochemical status of patients with ischemic heart disease].
Topics: Adult; Cardiovascular System; Coronary Artery Disease; Delayed-Action Preparations; Digestive System | 1997 |
Safe use of niacin.
Topics: Diabetes Mellitus; Humans; Hyperlipidemias; Niacin | 1997 |
ASHP Therapeutic Position Statement on the safe use of niacin in the management of dyslipidemias. American Society of Health-System Pharmacists.
Topics: Chemical and Drug Induced Liver Injury; Drug Monitoring; Gastrointestinal Diseases; Humans; Hyperlip | 1997 |
The new cholesterol education imperative and some comments on niacin.
Topics: Drug Therapy, Combination; Humans; Hyperlipidemias; Lipids; Niacin; Patient Education as Topic | 1998 |
Dental and gingival pain as side effects of niacin therapy.
Topics: Aged; Gingiva; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Niacin; Pain; Toothache | 1998 |
The effect of the mode of administration on the hypolipidaemic activity of niacin: continuous gastrointestinal administration of low-dose niacin improves lipid-lowering efficacy in experimentally-induced hyperlipidaemic rats.
Topics: Animals; Aspartate Aminotransferases; Cholesterol; Cholesterol, Dietary; Drug Administration Schedul | 1998 |
A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.
Topics: Cholesterol, LDL; Delayed-Action Preparations; Female; Flushing; Humans; Hyperlipidemias; Hypolipide | 1998 |
[Lipid and non-lipid effects of enduracin in patients with arterial hypertension].
Topics: Blood Flow Velocity; Blood Pressure; Cerebral Arteries; Cerebrovascular Circulation; Female; Humans; | 1999 |
Dietitian intervention improves lipid values and saves medication costs in men with combined hyperlipidemia and a history of niacin noncompliance.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit | 2000 |
Diagnosis, management and prevention of the common dyslipidaemias in South Africa--clinical guideline, 2000. South African Medical Association and Lipid and Atherosclerosis Society of Southern Africa Working Group.
Topics: Cholestyramine Resin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hydroxyme | 2000 |
Pharmacodynamic effects of bezafibrate and niacin combination: implications of the mode of administration.
Topics: Animals; Bezafibrate; Cholesterol; Drug Therapy, Combination; Hyperlipidemias; Hypolipidemic Agents; | 2000 |
Co-administration of equimolar doses of betaine may alleviate the hepatotoxic risk associated with niacin therapy.
Topics: Animals; Betaine; Homocysteine; Hyperlipidemias; Liver; Niacin; Rats; S-Adenosylmethionine | 2000 |
Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia.
Topics: Adult; Anticholesteremic Agents; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Male; M | 2001 |
[Indications for the pharmacologic treatment of hyperlipidemias].
Topics: Bile Acids and Salts; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypol | 2000 |
Hyperlipemia: a role in regulating UCP3 gene expression in skeletal muscle during cancer cachexia?
Topics: Animals; Blotting, Northern; Cachexia; Carrier Proteins; Fatty Acids, Nonesterified; Gene Expression | 2001 |
Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events.
Topics: Cardiovascular Diseases; Drug Therapy, Combination; Drug Tolerance; Female; Humans; Hydroxymethylglu | 2002 |
Lipid-lowering drug use and cardiovascular events after myocardial infarction.
Topics: Cholesterol; Clofibrate; Cohort Studies; Coronary Artery Disease; Coronary Disease; Female; Humans; | 2002 |
Enzyme activities along the tryptophan-nicotinic acid pathway in alloxan diabetic rabbits.
Topics: 3-Hydroxyanthranilate 3,4-Dioxygenase; Animals; Carboxy-Lyases; Cholesterol, Dietary; Diabetes Melli | 2002 |
Relation between arteriographically diagnosed femoral atherosclerosis and serum lipids. Prevalence and treatment in hyperlipidaemic subjects.
Topics: Adult; Aged; Aorta, Abdominal; Aortic Aneurysm; Arteriosclerosis; Drug Therapy, Combination; Femoral | 1992 |
Effects of nicotinic acid treatment on fatty acid composition of plasma lipids and adipose tissue in hyperlipidaemia.
Topics: Adipose Tissue; Adult; Aged; Fatty Acids; Female; Humans; Hyperlipidemias; Lipids; Male; Middle Aged | 1992 |
Niacin benefits.
Topics: Humans; Hyperlipidemias; Niacin | 1992 |
Clarification. Drug therapy for hyperlipidemia: when reducing cardiovascular risk is a priority.
Topics: Humans; Hyperlipidemias; Niacin | 1992 |
Hepatotoxicity associated with sustained-release niacin.
Topics: Aged; Chemical and Drug Induced Liver Injury; Delayed-Action Preparations; Female; Humans; Hyperlipi | 1992 |
Effect of bezafibrate & nicotinic acid on triton induced hyperlipidemias in CFY rats.
Topics: Animals; Bezafibrate; Cholesterol; Drug Therapy, Combination; Hyperlipidemias; Male; Niacin; Polyeth | 1991 |
Rediscovery of crystalline niacin.
Topics: Chemical and Drug Induced Liver Injury; Humans; Hyperlipidemias; Niacin | 1991 |
Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin.
Topics: Adult; Chemical and Drug Induced Liver Injury; Delayed-Action Preparations; Female; Humans; Hyperlip | 1991 |
Lactic acidosis associated with high-dose niacin therapy.
Topics: Acidosis, Lactic; Adult; Delayed-Action Preparations; Humans; Hyperlipidemias; Lactates; Male; Niaci | 1991 |
[Antilipemic agents and postprandial lipidemia].
Topics: Cholesterol; Chylomicrons; Coronary Artery Disease; Dietary Fats; Diterpenes; Female; Fenofibrate; H | 1990 |
The effects of nicotinic acid treatment on high density lipoprotein particle size subclass levels in hyperlipidaemic subjects.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug | 1990 |
Nicotinic acid in NIDDM.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Lipids; Niacin | 1990 |
The effect of serum lipid regulation on the development of femoral atherosclerosis in hyperlipidaemia: a non-randomized controlled study.
Topics: Adult; Analysis of Variance; Arteriosclerosis; Blood Pressure; Cholesterol, VLDL; Combined Modality | 1990 |
Treating hyperlipidemia, Part III: Drug therapy.
Topics: Aged; Enzyme Inhibitors; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias | 1987 |
Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic mice. A proposed model for drug screening.
Topics: Animals; Cholesterol, Dietary; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Fenofib | 1988 |
Potential problems with the widespread use of niacin.
Topics: Adult; Cholesterol; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Niacin | 1988 |
[Strains and species differences in experimental hyperlipidemia].
Topics: Animals; Clofibrate; Disease Models, Animal; Gemfibrozil; Glycerides; Hyperlipidemias; Hypolipidemic | 1986 |
Medical management of hyperlipidemia and the role of probucol.
Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gem | 1986 |
Current pharmacologic treatment of elevated serum cholesterol.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Co | 1987 |
Adverse effects of the treatment for hyperlipidemia.
Topics: Anion Exchange Resins; Anticholesteremic Agents; Bibliographies as Topic; Clofibrate; Diet; Drug The | 1986 |
[Drugs in hyperlipidemia].
Topics: Cholestyramine Resin; Clofibrate; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemi | 1987 |
[Drug treatment of hyperlipidemia].
Topics: Cholesterol; Coronary Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin; Risk Factors; | 1987 |
[Changes in lysozyme activity in hyperlipidemia and atherosclerosis in animals].
Topics: Adjuvants, Immunologic; Animals; Arteriosclerosis; Enzyme Activation; Hypercholesterolemia; Hyperlip | 1985 |
Xanthomas and hyperlipidemias.
Topics: Apoproteins; Arteriosclerosis; Cholestasis; Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyr | 1985 |